Paper No	Presenter	Title
1002	Dr Rukesh Yadav	Assessing the Utility of Serum Kallistan in the Diagnosis of Liver Cirrhosis: A Meta-analysis
1003	Thanh Quynh NGAN Le	Is drug- induced autoimmune hepatitis being underdiagnosed?
1004	Ngan Le Thanh Quynh	An acute flare of chronic hepatitis B in a patient with eosinophilic ascites and diabetic ketoacidosis represents a clinical challenge
1005	Ngan Le Thanh Quynh	Drug- induced autoimmune hepatitis, three case reports.
1008	Thaer Swaid	Efficacy and Safety of Terlipressin versus Octreotide for esophageal variceal bleeding: A retrospective study at a tertiary hospital in the UAE
1012	Ziad W. Elmezayen	Thromboangiitis obliterans in a Non-Smoker Complicated by Budd-Chiari Syndrome: A Rare Case of Visceral Thrombosis
1014	Jiyang Chen	Validation of the CLIF-SIG score in patients with HBV-related acutely decompensated cirrhosis
1015	Jiyang Chen	Gut Microbial Succession and Escalating Antibiotic Resistance from Chronic Hepatitis B to Acute-on-Chronic Liver Failure: A Metagenomic Study
1016	Xianbin Xu	Single-cell analysis identifies RETN+ monocyte-derived resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure
1024	Ulil Albab Habibah	Comparison of effectiveness of mycophenolate mofetil associated with standard dosage or reduced-dose tacrolimus for liver transplantation immunosuppression
1026	Lilit Harutyunyan	EXPLORING LABORATORY VARIATIONS IN CIRRHOSIS ETIOLOGIES: A COMPARATIVE ANALYSIS OF CBC AND LIVER SYNTHETIC FUNCTION BETWEEN PATIENTS WITH ALCOHOLIC LIVER DISEASE AND OTHER ETIOLOGIES
1027	Eliza Vashakidze	Long-term follow-up of HCV patients who treated with DAA [Direct-Acting Antivirals]
1028	Eliza Vashakidze	Chronic viral hepatitis [HCV, HBV] course and outcome in patients with severe COVID 19]
1030	Chaojian He	A case of drug-induced liver injury caused by salt-fleshed psoralea corylifolia
1031	Chaojian He	Idiopathic Inflammatory Myopathy Presenting as Hepatic Injury: A Case Report
1032	Chaojian He	Drug-Induced Liver Injury from Shenbao Tablets in an Elderly Patient: A Case Report
1033	Zyrah Lou Samar	A Rare Case of Peptic Ulcer Perforation Associated with Lenvatinib in Hepatocellular Carcinoma
1036	Chaojian He	Two cases of drug-induced liver damage in the elderly caused by Tusanqi (Gynura japonica)
1038	Chao WANG	Comparative Analysis of Epidemiological Characteristics of Hepatitis A and Hepatitis E in Beijing from 2015 to 2024
1040	Ziteng Wang	Small Intestinal Bacterial Overgrowth: A Missing Link in Gut–Liver Axis Dysregulation of MASLD
1041	Ningrui Su	Controlled Attenuation Parameter Factors and Steatosis Grading in Metabolic Dysfunction-associated Steatotic Liver Disease
1043	Xinjie Li	Non-invasive detection of occult yet significant liver pathology in ALT-normal chronic hepatitis B: a multicenter study
1044	John Derek Clutario	Multifactorial Anemia Unveiling Gastric Antral Vascular Ectasia in a Stage IV Breast Cancer Survivor: Endoscopic Resolution with Argon Plasma Coagulation
1047	Gang Li	Comparative Analysis of Epidemiological Characteristics and Co-infection of Hepatitis B and Hepatitis C in Beijing from 2010 to 2024
1048	Quanyi Wang	Analysis of the Epidemiological Characteristics of Hepatitis B in Beijing from 2008 to 2024
1049	Charles Gallaher	Rifaximin to reduce the risk of overt hepatic encephalopathy in patients undergoing TIPS - real world experience in a diverse population
1052	Liying Ren	Pan-cancer analysis identifies hemopexin as a tumor suppressor in HCC via TNF-alpha-mediated mitochondrial apoptosis
1053	Liying Ren	Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study
1057	Xinjie Li	Serum N-glycomics for non-invasive detection of significant liver pathology across clinical phases of treatment-naïve chronic hepatitis B
1058	Xinjie Li	Serum N-glycomics for non-invasive detection of significant liver pathology across clinical phases of treatment-naïve chronic hepatitis B
1059	huiling zhu	The predictive value of different frailty assessment tools for the prognosis of hospitalized patients with liver cirrhosis
1060	Firdian Makrufardi	Transitional Hepatocytes and Mortality-Associated Gene Programs Drive NASH-Associated Liver Cancer Revealed by Single-Cell Transcriptomics
1061	Firdian Makrufardi	Integrative AI-Based Multi-Omics Approach to Uncover Endothelial Diversity and Predict Cholestatic Liver Disease Across Vulnerable Populations
1062	Peng Qiu	GALNT7-Mediated Glycosylation of TAZ at Serine 307 Promotes Gallbladder Cancer Progression via Stabilization and Feed-Forward Activation
1063	Yuhong Suo	Paraspinal Vein Shunt: A Potential Key Factor Leading to Hepatic Myelopathy
1064	Yaqian Mao	Analysis of clinical characteristics and risk factors of liver injury in treatment-naïve patients with lung cancer
1066	Changle Wu	Efficacy of laparoscopic-assisted Microwave Ablation for treating giant hepatic hemangioma: a retrospective controlled study
1068	Baoju Wang	Gut Microbiota-Derived 3-Methylxanthine Regulating T-Cell Immune Response to Inhibit Viral Replication and Liver Injury in Chronic Hepatitis B comorbid with Metabolic Dysfunction-associated Fatty Liver Disease
1070	Quanyi Wang	Analysis of Epidemiological Characteristics and Risk Factors of Liver Function Impairment Among Middle-Aged and Older Community Residents in Beijing
1074	Arivarasan Barathi	Mediating role of BMI in alcohol-linked liver enzyme elevation among adults at a tertiary care hospital in South India
1077	Benjaphol Panyapornsakul	Performance of BAVENO VI and BAVENO VII Criteria for Excluding High-Risk Esophageal Varices in Compensated Cirrhosis with Hepatocellular Carcinoma

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1078	REBEKA SULTANA MOUSUMI	“When Treatment Triggers Disease: Hepatic Abscess as a Paradoxical Reaction to Antitubercular Therapy”
1081	Kapil Khanal	Risk factors and outcomes of carbapenem-resistant enterobacteriaceae infection in liver transplant patients: a systematic review and meta-analysis
1082	Fatih Işık	Prediction of Hepatic Functional Reserve Using a Novel “Severity Index” on Hepatobiliary Phase Gadoxetic Acid–Enhanced MRI
1083	Fatih Işık	Functional Liver Imaging Score on Gadoxetic Acid–Enhanced MRI: Correlation with MELD-Na, ALBI, FIB-4 and Clinical Status in Chronic Liver Disease
1084	Yuwei Wang	Long-Term Virological Response Dynamics and Clinical Outcomes in HBV-Related Cirrhosis: A Real-World Cohort Study
1086	Yuwei Wang	COVID-19 Pandemic's Impact on the Global Disease Burden of HBV-related Hepatocellular Carcinoma in the Elderly
1087	AHMET UYANIKOGLU	Bibliometric Analysis and Research Trends of Specialty Theses on Cirrhosis in Turkey
1088	JUNYI WANG	The cGAS-STING-IFITM3 Axis Drives Monocyte Phenotypic Shift and Immune Dysregulation in Acute-on-Chronic Liver Failure
1089	Ruilian Ma	CEP290: a primary cilium-related gene as the positive feedback regulator of Nrf2 that modulates liver cancer cells ferroptosis
1090	Vedat Goral	Hermansky-Pudlak syndrome (HPS)
1092	Vedat Goral	Triple A (Allgrove) Syndrome
1093	Burcu Çalışkan Demirkıran	Towards HCV Elimination: Time for Clinical and Laboratory Collaboration
1094	Yuxin Liang	Oxidative Stress–Immunotherapy Gene Signatures Define Prognosis and Immune Subtypes in Hepatocellular Carcinoma
1095	Yuxin Liang	Efficacy and safety of postoperative adjuvant HAIC combining lenvatinib with or without PD-1 inhibitors in solitary large HCC: A multicenter retrospective study
1097	juliette PONT	The Roadtrip : PEERS AND MEDICAL STAFF IS THE BEST MATCH TO TEST AND TREAT DRUG USERS FOR HEPATITIS C
1100	Chenxi Liu	MRI differential diagnosis of hepatic metastasis of choroidal melanoma in the patient with hepatitis B cirrhosis
1105	Asif Khan	Comparative Efficacy of NSAIDs and Opiates in Alleviating Pain Associated with Mild to Moderate Pancreatitis: A Randomized Controlled Trial
1106	Asif Khan	BEDSIDE NUTRITIONAL ASSESSMENT IN PATIENTS WITH LIVER CIRRHOSIS USING MINI NUTRITIONAL ASSESSEEMENT PROFORMA
1107	Takatsugu Tanaka	Serum fibroblast growth factor 21 as a novel biomarker of cachexia in chronic liver disease
1108	Fatih Albayrak	Comparison of Liver Biopsy with Shear-Wave Elastography and Other Non-Invasive Fibrosis Markers in Chronic Hepatitis B
1109	Mohamed Hamouda Elkasaby	Stereotactic body radiation therapy as an add-on to targeted agents in patients with locally advanced hepatocellular carcinoma
1111	Mark Angelo Pado	Effectiveness and safety of Fibrate Therapy in the treatment of adults with Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis
1114	Muhammed Bekçibaşı	Detection of HBV and HCV seroprevalence using rapid point-of-care tests among earthquake survivors in Southeastern Türkiye
1115	Wei Lv	Effectiveness and Follow-up Challenges of Sofosbuvir/Velpatasvir in HCV/HIV Co-infected Patients: A Real-world Experience from a Chinese Cohort
1119	Eda Kaya	Metabolic Associated Fatty Liver Disease in Obese and At-Risk Children and Adolescents in Türkiye: A Meta-Analysis of Prevalence
1120	Xingru Wang	Research Trends of Targeted Drugs for Nonalcoholic Fatty Liver Disease: A Bibliometric Analysis (2004–2024)
1124	He Ma	Single-arm meta-analysis and systematic review on clinical cure of chronic hepatitis B after hematopoietic stem cell transplantation: immunoregulatory mechanisms and clinical translational insights
1128	Daxian Wu	Zinc-alpha 2-glycoprotein (ZAG) emerges as a diagnostic biomarker for Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF)
1129	Vipul Gautam	Efficacy of albumin infusion for hypoalbuminemia in post-operative period in living donor liver transplantation – An open label randomized controlled trial
1131	Yani Zhou	Dietary Total Antioxidant Capacity and Metabolic Dysfunction-Associated Steatotic Liver Disease: a cross-sectional study
1135	Zhiyuan Hao	Impact of Low-Dose Rifaximin on Gut Antibiotic Resistance Genes in Patients with Decompensated Cirrhosis
1136	Carmela Bianca Villacete	Catastrophic unmasking: Fatal tuberculosis-associated Immune Reconstitution Inflammatory Syndrome presenting as acute liver failure in pregnancy
1138	Pengyuan Kang	Peripheral Single-Cell Immune Profiling of HBsAg Loss in HBV-Related Hepatocellular Carcinoma Receiving Anti-PD-1 Therapy
1142	Mahmuda jahan Jahan	From Naïve to Non-Responders under DAA Pressure: Unveiling NS5A and NS5B Resistance Associated Substitutions in HCV Genotype 3a from Bangladesh
1143	Mengbo Wu	Association between AST/ALT ratio and Hemodynamic Parameters of Carotid Arteries in Patients with Primary Aldosteronism: A Cross-Sectional Study
1145	Xin Song	Targeting Cancer-Associated Fibroblast Subpopulations and Metabolic Pathways to Enhance Immunotherapy in Hepatocellular Carcinoma
1146	Dorota Zarębska-Michaluk	Treatment with direct-acting antivirals in HCV-infected patients after liver transplantation
1148	Yuling Liang	Deciphering the Mechanism of Aristolochic Acid I-Driven Hepatocellular Carcinoma through Integrated Network Toxicology and Bioinformatics
1150	Yi-Chung Hsieh	Evaluation of high-sensitivity HBcrAg and HBsAg assays as biomarkers for occult HBV infection and hepatocellular carcinoma risk
1151	Grace Wong	HDV Screening Practices in Chronic Hepatitis B: Real world Data from a Decision Support App in the Context of Global Guidance
1152	Yang Wang	Clinical Efficacy of Robot-Assisted Biliary-Enteric Reconstruction in Radical Resection of Hilar Cholangiocarcinoma: Single-Center Practical Experience
1154	Abu Saleh Md Sadequl ISLAM	Clinical and epidemiological profile of Hepatitis A outbreak among medical students at Shaheed Ziaur Rahman Medical College hostel: A cross-sectional study

Paper No	Presenter	Title
1155	Ching-Chu Lo	MASLD AND GLYCEMIC IMPROVEMENT AFTER SUSTAINED VIROLOGIC RESPONSE IN TYPE 2 DIABETES PATIENTS WITH CHRONIC HEPATITIS C: A THREE-YEAR FOLLOW-UP STUDY
1160	Xianzhang Luo Luo	Study on the Mechanism of Samhd1 Mediated NEMO Polyubiquitination in Liver Ischemia-Reperfusion Injury
1161	Mohamad Jamalinia	Recurrence and Post-Liver Transplant Outcomes in Hepatocellular Carcinoma: Experience from the Main Center of Iran
1166	Feng Ren	Endoplasmic Reticulum Stress-Mediated PPARα-DDX3X Interaction Modulates Con A-Induced Liver Injury in Mice
1169	Victoria To	Associations between glycaemic indices and non-invasive markers of hepatic steatosis and steatohepatitis in Chinese adults with prediabetes
1171	Ojas Vijayanand Potdar	Optimizing Renal and Urological Outcomes in Liver Transplant Recipients: A Urologist-Driven Peri-Transplant Care Pathway at a Tertiary Transplant Center
1175	Qingyun Xie	First Clinical Evidence of Temperature-sensitive Liquid-Embolic Agent TACE Remodeling Immune Microenvironment in Unresectable HCC: Multicenter Propensity-Weighted Cohorts Study
1180	MANISH KUMAR	Study of Serum Trace Elements (Zn, Cu, Mg) in Hepatic Encephalopathy
1181	Edmond Baghdasaryan	Familial Mediterranean Fever as a cause of hepatic amyloidosis and decompensated liver cirrhosis
1182	Guixin Li	The NF-κB-TNFAIP3 axis attenuates MAFLD via activation of hepatocyte autophagy
1183	Zhenghua Luo	Study on the Mechanism of FBXW5 Inducing MKRN1 Ubiquitination and Degradation in Reducing Liver Ischemia-Reperfusion Injury
1184	Lei Dou	Study on the Mechanism of TRIM69 Binding to CRYAB Promoting TRAF6 Autoubiquitination and Aggravating Liver Ischemia Reperfusion Injury
1186	Vipul Gautam	Timing Transplantation versus Medical Treatment in Acute Liver Failure and Associated Outcomes: Insights from an Indian High-Volume Transplant Centre
1187	Vipul Gautam	Optimized Outcomes Using the Medial Reduction Technique for the Left Lateral Segment in Infants Undergoing Living Donor Liver Transplantation
1188	Jia Liu	Role and Mechanism of membrane CD100 in Regulating the Activation and Differentiation of HBV-Specific CD8 T Cell
1191	Sıla Akhan	Identification of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk Factors in People Living With HIV
1192	Yusuf Bünyamin Ketenci	Incidental Diagnosis of Rotor Syndrome in an Adolescent Presenting with Osteoporosis
1193	Chen Liang	Magnesium Isoglycyrrhizinate for Preventing Novel Antitumor Drug-Induced Liver Injury in Patients with Hematologic Malignancies: A Multicenter, Retrospective Study
1194	Md Shakhawat Hossain	The Silent Summer Threat: Significant Seasonal Worsening of Electrolyte Imbalance in Cirrhosis Patients in a Tropical Climate Calls for Dynamic Diuretic Dosing
1198	Arun B Jesudian	Multidimensional Burden of Hepatic Encephalopathy and Overt Hepatic Encephalopathy among U.S. Patients with Cirrhosis
1199	Hishan Abdelaal	Efficacy of Endoscopic band ligation versus argon plasma coagulation in Gastric Antral Vascular Ectasia management
1200	Bandar Aljudaibi	CAD-LT Score and Outcomes after Liver Transplantation: Insights from a Middle Eastern Cohort
1202	Chitchai Rattananukrom	A 10-year Cohort Study of The Overall Survival and Treatment Outcomes in Patients with Primary Biliary Cholangitis A Single-Centered Retrospective Cohort Study
1203	Chitchai Rattananukrom	PIVKA-II Monitoring to Predict Response of The First Transarterial Chemoembolization (TACE) in Intermediate Stage of Hepatocellular Carcinoma
1205	Jaejun Lee	Real-World Experience of 25 Years of Lamivudine Therapy: Highlighting Favorable Long-Term Outcomes in Chronic Hepatitis B
1206	Lalit Chandra Kummetha	Neurophysiological, neuropsychological characteristics and natural history of liver cirrhotics with minimal and grade 1 hepatic encephalopathy
1207	Shrey Bhatt	Comparison of inflammatory markers, magnetic resonance spectroscopy findings and outcomes in cirrhotic patients with minimal and grade 1 hepatic encephalopathy: a prospective observational study
1208	Milan Mishkovikj	Insights from the ELPA European Liver Screening Week 2025
1210	Fengna Yan	Prevotella-Derived Butyrate Inhibits CD8⁺ T Cell Glycolysis via AKT/mTOR signal to Alleviate MASH
1211	Makoto Moriyama	Differential Impact of Antiviral Therapy on Bimodal Recurrence Patterns in HBV versus HCV-related Hepatocellular Carcinoma Following Radiofrequency Ablation
1213	Celine Der-Torossian	Treatment Efficiency of Bulevirtide in Chronic Hepatitis Delta: Number Needed to Treat Analysis From the MYR301 Phase 3 Trial
1216	GAURAV TRIPATHI	Microbial hippurate promotes GLRA2 activation, immune exhaustion and development of shock in ACLF patients
1217	GAURAV TRIPATHI	Integrated Plasma Multi-Omics Identifies Fungal Dysbiosis and Lipid Remodelling as Major Determinants of Sepsis and Shock in Alcohol-Related Cirrhosis
1218	Yuhao Su	Development and Validation of a Nomogram to Predict Surgical Resection After Conversion Therapy in Initially Unresectable Hepatocellular Carcinoma
1220	Jun Chen	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for the Retreatment of Chronic Hepatitis C Patients Relapsed after DAA Treatment
1221	Yuhao Su	Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta-analysis
1222	Weixuan Xu	Efficacy and Safety of Radiotherapy Combined with PD-1 Inhibitors and Targeted Therapy for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Study
1223	Aizirek Abdikaiyrova	Prevalence and topographic extent of gastric intestinal metaplasia in cirrhosis versus dyspeptic controls: İmplications for premalignant risk
1224	Aizirek Abdikaiyrova	Clinical significance of Helicobacter pylori infection in cirrhotic patients: İmplications for the development of premalignant gastric lesions
1227	Ying Xiao	Comparative analysis of serum amino acid levels and their potential as biomarkers in liver cirrhosis: A Systematic Review and Meta-Analysis

Paper No	Presenter	Title
1228	JOSE FERNANDO OBILLOS	Role of Angiotensin Receptor Blockers in the Treatment of Hepatic Fibrosis in Patients with Metabolic Dysfunction Fatty Liver Disease: A Meta-Analysis
1230	Sun Hyun Bae	Treatment outcome of radiotherapy for elderly hepatocellular carcinoma patients with comorbidity
1231	Huanwen Chen	A Simplified HCV care whole pathway model improves HCV diagnosis and treatment rate in hyperendemic areas : experience in Xing'an country from China
1234	Akira Kado	Associations of PNPLA3 and MBOAT7 Genetic Variants with Risk of Steatotic Liver Disease and Visceral Fat Accumulation in Adolescence
1235	Alaa Ramadan	Comparative Efficacy of Emerging Metabolic Therapies for MASLD and MASH: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
1236	Huaguo Xu	Multi-center analysis of HDV seroprevalence and epidemiological profile in Chinese HBsAg-positive inpatients
1240	Hasan Eruzun	Impact of Hand Grip Strength on the Clinical Course of Patients with Acute Variceal Bleeding: A Single-Center Prospective Observational Study
1241	Sharmin Sultana	Liquid Biopsy-Based Detection Of TP53 And TERT Gene Mutations In HBV-Induced Chronic Liver Disease and Hepatocellular Carcinoma Patients: Evidence From Bangladesh
1242	I-Jung Feng	Hormone therapy and metabolic risk interact to influence metabolic dysfunction associated steatotic liver disease incidence across the menopausal transition: a 10 year longitudinal cohort study
1244	Teiji Kuzuya	Cabozantinib as Third- or Later-Line Therapy After ICI Failure: Real-World Outcomes of Reduced-Dose Strategies in Advanced HCC
1246	Purevsod Lkhagvasuren	TRENDS IN HEPATOCELLULAR CARCINOMA INCIDENCE IN MONGOLIA: A DECADE OF NATIONAL DATA (2014–2024)
1247	Junfeng Li	Clinical characteristics and prognosis of patients with primary biliary cholangitis: a single center experience in Lanzhou city, China
1248	Ying Shen	Progress Toward WHO 2030 Hepatitis B Mortality Target in the Asia–Pacific Region
1249	Jae Hyun Yoon	RE-LIVE Study (Re-Linkage to Pan-Viral Hepatitis): Interim Results from a Multicenter Observational Study on Care Engagement in Chronic Viral Hepatitis
1251	Shengjiang Deng	ANXA4 Deficiency Ameliorates Acetaminophen-Induced Acute Liver Injury
1253	Kapil Kumar	Clinical Trajectories of Acute Decompensation in Cirrhosis: The First Prospective PREDICT-Based Study from India
1255	SUSHMITA PANDEY	Chenodeoxycholic Acid Modulation via Bacteroides intestinalis AM1 underscores a Novel Approach in Acute Liver Failure
1256	Yu Huang	Evaluation of Information Quality and Reliability of Chronic Hepatitis B-Related Short Videos on TikTok and Bilibili
1258	春润 李	The Liver in Systemic Diseases: A Key Metabolic Regulator
1259	春润 李	The Central Role of Liver Dysfunction in Systemic Metabolic and Cardiovascular Diseases Remaining characters
1260	春润 李	Mitochondrial Dysfunction in NAFLD: A Public Health Perspective Remaining characters
1261	春润 李	Single-Cell Atlas Reveals Immunometabolic Drivers of NAFLD-HCC Transition Remaining characters
1262	春润 李	Gut Microbiota-Derived Metabolites Predict Advanced Fibrosis in MAFLD: A Machine Learning Approach Remaining characters
1264	Hishan Abdelaal	Efficacy of Percutaneous Microwave Ablation in Exophytic Hepatocellular carcinoma
1267	WEN GAO	Clinical Characteristics and Prognostic Analysis of Patients with Primary Biliary Cholangitis Complicated with Hepatic Granulomas
1268	Enkhtaivan Odmaa	CURRENT SITUATION OF ACUTE VIRAL HEPATITIS IN MONGOLIA: A DECADE OF NATIONAL DATA
1269	Badamnachin Batsukh	RISK FACTORS AND CLINICAL FEATURES OF ACUTE HEPATITIS D IN MONGOLIA
1270	Lkhagvasuren Purevsod	Treatment Outcomes of HCV Genotype 1b with Ledipasvir/Sofosbuvir and the Role of Resistance-Associated Substitutions in Mongolia
1271	Ganbaatar Khorolgarav	CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS D VIRUS INFECTION IN MONGOLIA
1273	Xiaoxiao Yu	Community-based interventions for hepatitis C virus elimination among people who use drugs in Shanghai, China
1274	Jia-Yong Su	Constructing a dual-dimensional scoring system by integrating tertiary lymphoid structures and monocyte/lymphocyte ratio to optimize recurrence risk stratification in hepatocellular carcinoma: a multicenter cohort study
1275	Jia-Yong Su	Development and validation of an explainable machine learning model for predicting the recurrence of adjuvant PD-1 inhibitors in hepatocellular carcinoma patients at high risk of recurrence: a multicenter cohort study
1276	Yusuf Bünyamin Ketenci	Autoimmune hepatitis triggered by acute Coxiella burnetii infection: a case report
1279	Jia-Yong Su	Multicenter cohort study comparing adjuvant PD-1 inhibitors with active surveillance in hepatocellular carcinoma at high-risk of recurrence: Benefit in early, but not late recurrence
1282	Guanzhu Lu	Understand Current Treatment Experience, Unmet Needs, and Attitudes Toward Functional Cure in China Among Patients With Chronic Hepatitis B
1285	Faisal Aba-Alkhail	Safety and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from HBsAg-Positive Donors: A Case-Control Study from a Tertiary Care Centre.
1287	Brian Conway	Using Community Partnerships to Achieve HCV Micro-elimination in Vancouver's Inner-city
1288	Brian Conway	Strategies for reducing the time from HCV diagnosis to treatment initiation: Lessons from Vancouver, BC, Canada

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1290	Oidov Baatarkhuu	Safety and Tolerability of SIRT and Sorafenib in Advanced Hepatocellular Carcinoma in Mongolia
1291	Oidov Baatarkhuu	Comparison between SIRT and Sorafenib in Advanced Hepatocellular Carcinoma in Mongolia
1292	Tuvshinbayar Narangerel	Comparative Study of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B in Mongolia
1293	Badamnachin Batsukh	Evaluating ALBI Score for Risk Stratification in Acute Hepatitis B and D in Mongolia
1294	Badamnachin Batsukh	Clinical Features and Outcomes of Acute Hepatitis B and Delta in Mongolia: A One-Year Prospective Follow-Up Study
1295	Buyankhishig Nomin	HCC associated with hepatitis B and C Mongoloid and Caucasians of North-East Asia
1296	Oidov Baatarkhuu	Efficacy and Safety of Tenofovir Alafenamide in the Management of Chronic Hepatitis B in Mongolia
1297	Oidov Baatarkhuu	Clinical Characteristics of HBV- and HCV-Related Hepatocellular Carcinoma: A Comparative Study in Mongolia
1298	Oidov Baatarkhuu	Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia
1299	Oidov Baatarkhuu	Hepatitis C virus infection in Mongolia: Updated provincial data on prevalence, genotype distribution, and age-specific risk factors
1300	Khorolgarav Ganbaatar	Epidemiology, Clinical Features, and Laboratory Findings of Acute Hepatitis B and D Virus Infection Among Children Under Five Years of Age in Mongolia
1301	Purevsod Lkhagvasuren	Clinical and Metabolic Features of MAFLD Among Individuals With Chronic HCV
1302	Purevsod Lkhagvasuren	ASSOCIATION BETWEEN METABOLIC RISK FACTORS, HEPATIC STEATOSIS, AND QUALITY OF LIFE AMONG PATIENTS WITH CHRONIC HCV INFECTION ASSESSED USING THE HCV-SIQv4 QUESTIONNAIRE
1303	Purevsod Lkhagvasuren	Impact of Sleep Disturbances and Psychological Distress on Quality of Life in Mongolian Patients with Acute and Chronic Hepatitis C
1304	Yuanjun Lu	MiR-551a drives cholesterol metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma
1306	Purevsod Lkhagvasuren	MAFLD in Chronic HBV: The Dominant Role of Metabolic Dysfunction Over Viral Load
1307	Anton Purnomo bin Djailani	Assessment of Clinical Status and Liver Function as Predictors of Lenvatinib Efficacy in Hepatocellular Carcinoma: A Single-Center Study at Dr. Mohammad Hoesin Hospital Palembang (January–December 2025)
1309	Farzana Laila Laila	Unlocking CTNNB1 hotspot mutations from cell-free DNA (cf-DNA) in hepatitis B virus induced hepatocellular carcinoma: A cross-sectional study from Bangladesh
1313	Sang Youn Hwang	Combination of radiotherapy and durvalumab/gemcitabine/cisplatin therapy improve survival in biliary tract cancer (especially extrahepatic bile duct cancer) patients
1314	Xinyang Li	SDHA Deficiency in Hepatocellular Carcinoma Promotes Tumor Progression through Succinate-Induced M2 Macrophage Polarization
1315	Wenjing Wang	Clinical characteristics and combined pathogen spectrum of patients with influenza A in winter: a retrospective study based on targeted high-throughput sequencing detection
1317	Adhitya Wicaksana	Association Between Clinical Predictors And Albumin Billirubin Score In Hepatocellular Carcinoma Patients Receiving Lenvatinib At Dr. Mohammad Hoesin General Hospital, Palembang, During 2025
1318	Sang Youn Hwang	Atezolizumab and bevacizumab therapy combined with expanded NK cells significantly prolongs survival in vivo hepatocellular carcinoma model.
1319	Hua-xiang Yang	Integrated Proteomic and Metabolomic Profiling Reveals Distinct Immune and Metabolic Landscapes in Occult Hepatitis B Infection
1320	Leland J. Yee	Impact of Long-Term Oral Antiviral Treatment on Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B Who Are Hepatitis B e Antigen Positive Using the PAGED-B Score
1321	Akin Kose	Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR 301 study
1322	ESMA ASLIHAN AYDEMİR	COMPARISON OF SEROLOGICAL FIBROSIS MARKERS WITH LIVER BIOPSY FIBROSIS STAGES IN CHRONIC HEPATITIS B PATIENTS
1323	Akin Kose	Final results of MYR301 Phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up
1324	Ruoqi Zhou Zhou	Synergistic effects of type 2 diabetes and alcohol consumption on all-cause and liver-related mortality among patients with steatotic liver disease
1325	Ying Xiao	Serum metabolomic characteristics and their predictive value for ninety-day prognosis in patients with acute-on-chronic liver failure
1329	Shiyang Pan	Multi-center analysis of HDV seroprevalence and epidemiological profile in Chinese HBsAg-positive inpatients
1330	Pukar Thapa	Dapsone Syndrome Relapse: Unraveling a Complex Case
1332	bushra shahid	Socioeconomic Factors Among Chronic Liver Disease Patients :Experience From Largest Tertiary Care Hospital Of Pakistan
1333	Jiwon Yang	Impact of Prior Treatment Response on Survival Outcomes of Subsequent Systemic Therapies Following First-line Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
1339	Qing Ye	Clinical Investigation on Hepatocellular Carcinoma Complicated with Esophageal and Gastric Variceal Bleeding
1340	Kaicen Wang	Akkermansia muciniphila Regulating Cholangiocyte Pyroptosis via the Bile Acid-TGR5 Axis

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1342	Leland J. Yee	Exposure to Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate and the Risk of Hepatocellular Carcinoma
1343	Leland J. Yee	Impact of Long-Term Tenofovir-Based Treatment on Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B Using the reREACH-B Score
1345	Minseong Kim	Association of MASLD with Prevalence and Severity of GERD in Primary Care
1347	Jiarui Zheng	Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B:An observational study
1348	Huilan Tu	Activation of the 5-lipoxygenase in myeloid immune cells is associated with systemic inflammation in acute-on-chronic liver failure
1351	Cam Linh Le	Evaluation Of Hepatitis B Recurrence In Liver Transplant Recipients In Vietnam
1354	Anton Purnomo	Prognostic value of alpha-fetoprotein and hepatic reserve in hepatocellular carcinoma patients receiving lenvatinib: real-world evidence from Dr. Mohammad Hoesin Hospital Palembang
1355	春润 李	Adipocyte-derived Extracellular Vesicles Propagate Hepatic Metabolic Inflammation Remaining characters
1357	Hang Wang	Expression of the FCGBP Gene in Hepatocellular Carcinoma Tissues and Its Role in Prognostic Assessment
1358	Lingga Gumelar	CORRELATION OF INTERLEUKIN-17 SERUM LEVELS WITH DEGREE OF LIVER FIBROSIS IN CHRONIC HEPATITIS B PATIENTS AT MOHAMMAD HOESIN HOSPITAL PALEMBANG
1360	Honglian Gui	Gender-specific clinical characteristics and care cascade of HCV in east China: a multicenter, retrospective study
1363	Jinlin Hou	Combination therapy with HT-101 and HT-102 achieves rapid and progressive HBsAg loss in HBeAg-negative, nucleos(t)ide analogues-suppressed patients: 24-week results from an ongoing multicentre, open-label phase Ib/IIa study
1364	Chengxuan Yao	Exploring the Impact of Gut Microbiota on Itch in Cholestasis
1365	Junliang Fu	Sequential combination therapy of PD1 antibody and PEG-IFN α promotes HBsAg clearance and the restoration of specific T-cell response
1366	春润 李	Spatial Transcriptomics Uncovers Niche Driving Liver Fibrosis Remaining characters
1367	春润 李	TCM Constitution Types Predict MAFLD Risk and Pathology Remaining characters
1368	春润 李	Phlegm-Dampness Constitution Alters Gut Microbiome in MAFLD
1369	春润 李	Qi-Stagnation Constitution Primes Pro-inflammatory Liver Macrophages Remaining characters
1370	春润 李	Qi-Stagnation Constitution Primes Pro-inflammatory Liver Macrophages Remaining characters
1371	Ying Xiao	消耗流量: 707字/单词846/5000 字符 Multi-omics analysis reveals key mediators of 90-day prognostic predictive value in patients with acute-on-chronic liver failure
1372	AHMED ALMEZAINE	Survival Outcomes and Prognostic Nomogram in Primary Hepatic Angiosarcoma: Insights From a Population-Based Analysis
1373	Yujuan Guan	Constructing and Implementing a New Model for Viral Hepatitis Screening in Guangzhou's Primary Communities
1374	AHMED ALMEZAINE	Prognostic Influence of Histopathological Subtypes and Patient Characteristics in Hepatocellular Carcinoma: A Comprehensive Population-Based Evaluation
1376	Jian Wu	GP73: A novel non-invasive biomarker for diagnostic and prognostic of HEV-ALF elderly patients
1379	Ruoqi Zhou	Synergistic effects of type 2 diabetes and alcohol consumption on all-cause and liver-related mortality among patients with steatotic liver disease
1381	NATHANIEL CAMANGON	From Crisis to Control: Acute HCV-Triggered Acute-on-Chronic Liver Failure With HRS Successfully Stabilized With Early Sofosbuvir–Velpatasvir and Hemoperfusion: A Case Report
1382	Yufen Jiang	SARS-CoV-2 Spike Protein Promotes HBV Replication via Autophagy and Enhances Inflammatory Responses in Chronic Hepatitis B Patients with Liver Dysfunction and Metabolic Disorders
1383	Daniel Yi Nin Tung	Prognostic Impact of Cardiometabolic-Kidney Dysfunction on Patients with Metabolic dysfunction–associated steatotic liver disease (MASLD
1386	Bibek Gyanwali	Real-World Clinical Experience with Long-Term Albumin Therapy in Advanced Liver Disease: A Case-Based Perspective from Asia
1388	Sunyoung Lee	External Validation of a Preoperative Microvascular Invasion Risk Prediction Model Using Gadoxetate-Enhanced MRI for Predicting Early Recurrence After Surgical Resection in Patients With Single Hepatocellular Carcinoma
1390	JinNi Huang	A study on clinical factors influencing the recurrence of hepatitis B surface antigen following clearance after long-term nucleoside analogue therapy in patients with hepatitis B virus infection
1391	Xinhao Gao	Integrated Multi-omics Liquid Biopsy: Advancing Early Detection and Precision Management of HCC
1392	Jian-Hong Zhong	Feasibility of achieving a tumor- and drug-free state through conversion therapy followed by curative hepatectomy for patients with initially unresectable hepatocellular carcinoma
1394	RAJAT PRABHAKAR PANDE	Clinical landscape, Mutation mapping, Quality of life and Treatment outcomes in Adolescent and Adult Wilsons disease patients in a South Indian cohort.

Paper No	Presenter	Title
1395	Yuerong Zhang	Four-Year Management of Unresectable Hepatocellular Carcinoma: Sustained Tumor Control and Cumulative Multi-Organ Toxicities
1397	Hua-xiang Yang	Ammonia-Seeking Zinc Micromotors for Active Ammonia Scavenging in Hepatic Encephalopathy
1398	Joemon M George	A Study to assess the relationship of Frailty and Myosteatosis in Cirrhotic patients
1400	Ediz Tütüncü	The Silent Risk of Steroid Therapy: A Case of HBV Reactivation
1402	Leeland Yee	Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Phase 1b Study Results From Virally Suppressed Patients With Chronic Hepatitis B
1403	Fatema Safri	Developing Blood-based Lipid Biomarker for Hepatocellular Carcinoma Risk Prediction in Non-cirrhotic MAFLD Patients
1404	Yaxin Li	A Model for Prediction Hepatic Nodules Development to Hepatocellular Carcinoma in Patients with HBV-Related Cirrhosis on Antiviral Therapy
1405	Hyuk Kim	Impact of Smoking on the Longitudinal Progression of Liver Fibrosis
1406	So Kyung Yoon	Assessing the Efficacy of donor-derived cell-free DNA (ddcfDNA) Measurement in Liver Transplant Recipients for Rejection Diagnosis and Therapeutic Response Evaluation : A case report
1407	So Kyung Yoon	Osteoclast-like giant cell tumor of the intrahepatic bile duct: a rare neoplasm with a stable clinical course: A case report
1409	Yaxin Li	Alcohol-Associated Liver Cancer Burden Among Young Adults: Comparing China With Global Trends From GBD 2021
1411	Mengxia Sun	Impact of gut microbiota on the aggravation of NAFLD development in high-fat diet mice with circadian rhythm disruption
1412	Hee Jin Park	Lactobacillus acidophilus Modulates the Gut–Liver Axis and Ameliorates MASLD and Type 2 Diabetes–Related Metabolic Dysregulation
1413	Sanju Yadav	Bile fungal diversity correlated with severity and is predictive of carcinoma in patients with CAGB
1420	Haoshuang Fu	Machine learning model based on systemic metabolic factor for mortality prediction in acute hepatitis E virus infection: development and validation from a dual-center cohort
1421	Ki Tae Suk	Pharmabiotics, Phocaeicola dorei, ameliorates liver fibrosis by alleviating macrophage efferocytosis of neutrophils
1424	Qinzhi Deng	Comparing two intervention strategies to improve hepatitis B virus deoxyribonucleic acid testing rate among hepatitis B surface antigen-positive hospitalized patients
1425	Morten Karsdal	Fibroblast activation assessed by PRO-C3 and PRO-C6 is associated to accumulation of key bile acids - A hallmark of fibrosis initiation and mortality in alcohol-related liver disease
1427	Bootsakorn Boonkaew	Protein-tyrosine phosphatase 1B promotes hepatic stellate cell activation via SRC signaling
1428	Sang-Hoon Kim	Surgical Resection Versus Non-Surgical Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Comprehensive Systematic Review and Meta-Analysis
1429	Guoyun Xuan	Meta analysis of efficacy and safety of CAR-NK cell in the treatment of primary liver cancer
1430	Rune Vestermark	Fibrosis non-invasive test panel (FIB-NIT): A novel biomarker panel for investigating fibrosis dynamics through individual components of fibrogenesis (PRO-C3), fibrolysis (CTX-III), and clinical outcomes (PRO-C6) in alcohol-related liver disease
1432	Qian Wang	Longitudinal Changes in Skeletal Muscle Index Among Patients With Cirrhosis: A Mixed-Effects Analysis in an Observational Cohort
1433	Yuki Tamaki	Functional changes following hepatocyte transplantation in mice with liver injury
1434	Jun Chen	Awareness and Treatment Status of Patients with Chronic Hepatitis B: Results from a Single Center Patient Survey in Hunan province, China
1435	liang Peng	Individualized nutrition support improves outcomes in hepatitis B virus-related acute on chronic liver failure patients at nutritional risk: a randomized controlled trial
1437	YIJING ZHANG	Efficacy of Sequential or Combined Tenofovir Alafenamide in Entecavir-Treated CHB Patients with Low-Level Viremia and Its Impact on Lipid Levels
1438	Akin Kose	Efficacy and safety of seladelpar in patients with primary biliary cholangitis previously treated with fibrates or obeticholic acid
1439	Lela Inaishvili	Liver stiffness;based assessment of fibrosis stages in chronic hepatitis B patients in Georgia: associations with viral, clinical and demographic factors
1440	Clinton Owusu Boateng	Prevalence and predictors of hepatitis B virus infection among sellers and workers at West Africa’s largest market, Kejetia, Ghana: a cross-sectional study
1441	Akin Kose	Disease control as evidenced by transient elastography in the ASSURE study: 36 months of seladelpar treatment is associated with stable or improved liver stiffness in patients with primary biliary cholangitis
1442	Yue Kong	Combination Therapy Using DPCAS Mode and DPMAS Mode of Artificial Liver Support System for Severe Liver Injury with Sepsis: A Case Report
1443	Akin Kose	Seladelpar is associated with sustained reductions in cholestatic markers and a consistent safety profile in patients with primary biliary cholangitis up to 48 months in the ongoing, open-label ASSURE study
1444	Akin Kose	Sustained and clinically meaningful improvements in moderate to severe pruritus patients with primary biliary cholangitis treated with seladelpar: results from the ASSURE study up to 30 months

Paper No	Presenter	Title
1445	Yuhong Liu	Sirtuin 3 ameliorates acute-on-chronic liver failure via the glutathione peroxidase 4/mixed lineage kinase domain-like protein-mediated ferroptosis-necroptosis interplay
1446	Alexey Goncharov	Metabolic dysfunction-associated steatotic liver disease in patients with diabetes mellitus is linked with the severity of metabolic disorders.
1448	Brian Conway	Insights from 10 years of Hepatitis C testing in Vancouver's inner-city
1449	Marybel Garcia-Rodriguez	Efficacy of low-dose versus standard-dose terlipressin in patients with variceal hemorrhage: systematic review and meta-analysis of randomized controlled trials.
1450	Ying Zhu	The Impact of Hepatic Steatosis on Viral Load and Liver Fibrosis in Patients with Chronic Hepatitis B
1451	Ponkaj Naha	Diagnostic challenge in a young male patient presenting with feeling of upper abdominal lump and recent onset of black terry stool
1452	Conglin Zhao Zhao	Evaluation of Urinary Hepatitis E virus Antigen Colloidal Gold Immunochromatographic Assay in Clinical Diagnosis of Hepatitis E virus Infection
1453	Yijing Cai	The Impact of a Hospital-Wide Alert and Referral Program on the Management of Hepatitis B Virus (HBV) Infection in Non-Specialist Departments: A Before-and-After Study
1454	Sujun Zheng	Impact of Autoimmune Phenomena on the Clinical Presentation and Prognosis of Wilson's Disease: A Retrospective Cohort Study
1455	Po-Yu Huang	Cardiovascular Outcomes of GLP-1 Receptor Agonists vs SGLT2 Inhibitors in Metabolic-Associated Steatotic Liver Disease and Type 2 Diabetes: A Real-World Comparative Effectiveness Study
1457	Adela Turcanu	Predictors for re-hospitalization in liver cirrhosis: the first longitudinal cohort study in the Republic of Moldova
1458	John Derek Clutario	DIAGNOSTIC ACCURACY OF PIVKA-II IN DETECTING HEPATOCELLULAR CARCINOMA AMONG AFP-NORMAL PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
1460	Lei Shi	Dysregulated S100A8/A9–Monocyte Pathway in Cirrhosis-Associated Immune Dysfunction and Its Reversal by Mesenchymal Stromal Cells
1462	Baohua Wu	Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients with decompensated cirrhosis: a retrospective study in Qinghai province
1464	Jing Liang	Liver Fibrosis and Cardiovascular Health Jointly Predict Mortality in NAFLD and MAFLD
1465	Chia-Jung Ho	Impact of metabolic dysfunction–associated steatotic liver disease on young hepatocellular carcinoma patients following curative resection
1467	Alexey Goncharov	Clinical and instrumental profile of patients with Cryptogenic steatotic liver disease
1470	Xiaoman Liu	Hepatitis E virus orchestrates mitochondrial fusion to drive viral replication through mechanistic coupling of pro-viral autophagy and innate immune evasion
1474	Xiaoman Liu	Deciphering the mechanistic underpinnings of hepatitis E severity: a tale of T cell exhaustion and maladaptive cDC2 activation at single-cell resolution
1475	Bobin Hu	Serum cystathionine γ-lyase (CTH) as a novel noninvasive biomarker for occult nonalcoholic steatohepatitis
1477	Yu-Ju Wei	A post-authorization study to evaluate the safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in the retreatment of chronic hepatitis C patients in Taiwan
1478	Ning Wang	Unveiling Pyruvate Metabolism: A Prognostic and Immunotherapeutic Beacon in Hepatocellular Carcinoma
1479	Li Bai	Disulfidptosis in Acute Liver Failure: Roles, Molecular Mechanisms, and Potential Clinical Applications
1480	Weifeng Zhao	Baseline Screening and Epidemiological Characteristics of First-Degree Relatives of HBV-Related Hepatocellular Carcinoma Patients: A Multicenter Prospective Study in Jiangsu China
1483	Qing Ye	Epidemiological Survey of Liver Cirrhosis in Tianjin: Ten-Year Data
1485	Xinhao Gao	Integrated Multi-omics Liquid Biopsy: Advancing Early Detection and Precision Management of HCC
1487	Meng Li	Sphingosine Attenuates Steatosis but Exacerbates Fibrosis Risk in Metabolic-Associated Fatty Liver Disease (MAFLD) via Hepatic LDLR Modulation
1488	Eri Nanizawa	Eicosapentaenoic Acid Prevents the Short-term High-fat Diet–Enhanced Severity of Concanavalin A–Induced Liver Injury
1489	Zhi-xiang Du	Transcriptomic profiling of liver biopsy tissues reveals αβ T Cell activation and differentiation are associated with Idiosyncratic drug-induced liver injury
1490	Prabhath Dasanayaka	South Asian metabolic phenotype and fibrosis discordance in lean and obese metabolic dysfunction–associated steatotic liver disease: insights from a Sri Lankan tertiary cohort
1491	Yanpei Mai	Dynamic network collapse in decompensated hepatic cirrhosis
1492	Lingling Yang	Evaluating the accuracy of the histological diagnosis in unexplained liver injury: A retrospective study
1495	Muhammad Fahad Zakir	Electrolytes as predicting factor on outcome in patient with cirrhosis: Study from low socioeconomic south-east Asian population.
1496	源 唐	Systemic Immune-Inflammation Index as a Predictive Biomarker for Non-Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
1498	Lingling Yang	A Case of Idiopathic Caroli Syndrome Misdiagnosed as Cholangiocarcinoma
1499	Lingling Yang	A case of drug-induced autoimmune hepatitis with negative serum markers
1500	Dinh Thang Nguyen	Endogenous Endophthalmitis Associated With Liver Abscess Caused By Klebsiella pneumoniae

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1501	Muhammad Fahad Zakir	Are third generation cephalosporin still considered first choice for ascitic fluid infection? in decompensated cirrhotic patients: Study from largest tertiary care hospital Pakistan.
1502	Lingling Yang	Chronic hepatitis B with autoimmune hepatitis in a male patient
1503	Ying Wang	Clinical Features and Prognostic Assessment of MAFLD-Related Cirrhosis: Pathological vs. Clinical Diagnosis
1505	Jihyun An	The Mechanistic Basis of ASH1L's Oncogenic Role in Hepatocellular Carcinoma
1506	Dr. Md. Tanveer Rahman Rashed	Effect of Semaglutide Therapy on Hepatic Steatosis and Liver Stiffness in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): A Quasi-Experimental Study
1508	Kseniya Gulyaeva	Minimal Hepatic Encephalopathy in Portal Vein Thrombosis: An Underrecognized but Common Complication
1509	Kseniya Gulyaeva	When Pressure Matters More Than Parenchyma: Gut Dysbiosis in Different Types of Portal Hypertension
1510	Wei Hou	INTEGRATED BIOINFORMATIC ANALYSIS OF THE ROLE OF SLC35B2 IN HEPATOCELLULAR CARCINOMA
1511	Wei Hou	A PAN-CANCER ANALYSIS OF THE ROLE OF OXCT1 IN HUMAN CANCERS
1512	Wei Hou	COMPREHENSIVE ANALYSIS OF THE ROLE OF TUMOR-ASSOCIATED ANTI-LMNB1 AUTOANTIBODY IN HEPATOCELLULAR CARCINOMA
1513	Wei Hou	PAN CANCER ANALYSIS OF HACD FAMILY AND UNRAVELLING THE ONCOGENIC ROLE IN HEPATOCELLULAR CARCINOMA
1514	Wei Hou	AN INTEGRATED ANALYSIS OF THE ROLE OF tsRNA-Asp-5-0002 IN HUMAN TUMORS ACROSS MULTIPLE CANCER TYPES
1515	Safaa M Abdelhalim	Investigating the Hidden Link: How Common Is MAFLD Among Cataract Patients?
1518	Oumaima Azzaoui	Performance of Non-Invasive Techniques for Quantifying Hepatic Steatosis: Limitations of Conventional MRI Compared with FibroScan in a Preliminary Moroccan Cohort
1519	Young Eun Seo	Real world outcomes of atezolizumab and bevacizumab according to clinical risk factors for unresectable hepatocelullular carcinoma: A multicenter CLCSG cohort study
1520	Zyrah Lou Samar	Hole in the Wall: A Rare Case of Lenvatinib-Associated Peptic Ulcer Perforation in Hepatocellular Carcinoma
1521	pengyu pan	Risk Factors for Liver Fibrosis Severity in Patients with Nonalcoholic Steatohepatitis: A Study Based on Liver Pathology
1522	Sung Bum Cho	Efficacy and safety of hepatic arterial infusion chemotherapy sequential therapy versus Atezolizumab/Bevacizumab in infiltrative hepatocellular carcinoma with portal vein thrombosis: A cohort study with Propensity score matching
1523	Ruochan chen	Anserine promotes Antibacterial Defense in Cirrhosis via the Mup11+ Hepatocyte-CD44+ pDC Crosstalk and CCL5-CCR5 Axis Short title: Anserine Promotes Antibacterial Defense via CCL5-pDC in Cirrhosis
1524	Prabhath Dasanayaka	Carbamazepine-induced cholestatic hepatitis with rapid fibrosis progression and biopsy-confirmed pure red cell aplasia in a young woman
1530	Xiao Han	Integrative lipidomic and transcriptomic analyses reveal glycosphingolipid remodeling in metabolic dysfunction-associated fatty liver disease-related advanced fibrosis
1532	Pei Zheng Lee	A Rare Case Of Acute Liver Failure (ALF) Secondary To Clozapine-Induced Autoimmune Hepatitis
1534	Yuelin Xiao	FABP4 Exacerbates Drug-Induced Cholestatic Liver Injury via NLRP3/GSDMD-Dependent Pyroptosis
1535	Shaorui Hao	Multimodal In-Hospital Alert Intervention Significantly Improves HBV-DNA Testing and Antiviral Treatment Rates among HBsAg-Positive Patients in Non-Specialty Departments
1536	Xiaoxin Wu	Diagnosis and treatment of occult primary hepatocellular carcinoma presenting with ovarian metastasis as the initial manifestation: a case report
1537	Hua-xiang Yang	Targeting the Cholangiocytes Vitamin D/TXNIP Pathway to Attenuate Ductular Reaction and Liver Fibrosis
1538	Wenying Qiao	Development and Validation of a RF-LASSO-Cox-Derived Nomogram Incorporating Inflammatory Markers to Predict Long-Term Survival in Early-Stage Hepatocellular Carcinoma after Microwave Ablation
1539	Yuelin Xiao	The FABP4/CD36/FXR Axis Regulates Bile Acid Homeostasis in Drug-Induced Cholestasis
1540	jing liang	Pruritus and Its Impact on Quality of Life in Primary Biliary Cholangitis: A Study of Patients on Long-Term Ursodeoxycholic Acid Treatment
1541	Wenying Qiao	Development and Validation of a Nomogram for Predicting Postoperative Survival in Patients with Multifocal Hepatocellular Carcinoma
1543	Wei Cheng	Endothelial RUNX1 Controls Acetaminophen-Induced Liver Injury by Regulating LSEC Dysfunction and Pathological Angiocrine Signaling
1544	Qi Wang	Alterations in gut microbiota and metabolism are correlated with the severity of PBC.
1545	Moon Haeng Hur	Significant Burden of Liver-Related Outcomes in DM-MASLD despite Low Fatty Liver Index: Results from Two Nationwide Cohort Studies
1546	Aaron Tsz-Wang Lo	Tranexamic acid on risks of rebleeding in acute variceal bleeding: a retrospective cohort study on local data in Hong Kong
1547	Mohamed Abdel-Samiee	Micro-RNAs (−122, −34a and −99a) as Potential Predictive Biomarkers for MAFLD
1548	Mohamed Abdel-Samiee	The Potential Role of A Gut Hormone in MAFLD
1549	Rachel Teo	Retrospective Audit of Terlipressin Use in Hepatorenal Syndrome – Acute Kidney Injury (HRS-AKI)

Paper No	Presenter	Title
1550	Shuying Song	VCTE Radiomics for Non-Invasive Assessment of Hepatic Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis
1553	Hua-xiang Yang	Hepatic G3BP1 Acts as a Critical Role Integrating Autophagy and Lipogenesis to Suppress MASLD Progression
1554	Mohamed Abdel-Samiee	Micro-RNA Gene Polymorphisms in Egyptian Cirrhotics who developed Hepatocellular Carcinoma
1556	Mohamed Abdel-Samiee	Serum kallistatin level in comparison to other noninvasive panels for potential portal hypertension Evaluation in Egyptian cirrhotics
1557	Xue Zhang	AADN score: Predicting Response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma
1558	Mohamed Abdel-Samiee	Detection of Small Fiber Neuropathy Changes by Sudoscan in Hepatitis C Virus Infected Cirrhotics
1561	Zimeng Shang	Cell-type-specific bidirectional modulation of Zfp36l2 by a Chinese herbal formula reverses T cell exhaustion to suppress hepatocellular carcinoma
1562	Munira Jahan	Evaluation of HBV RNA as a predictive biomarker to determine intrahepatic HBV activity among chronic hepatitis B virus infected patients
1563	Xinyu Liu	Dynamics of Fibrosis Regression and Long-term Liver-related Events in Patients with Compensated Cirrhosis: A 13-year Prospective Cohort on Entecavir Therapy
1566	Huan Liu	Enrichment of intratumoral Cutibacterium acnes in Advanced Hepatocellular Carcinoma and its promotive role in tumor progression
1569	Ismail Qarch	Impact of Thrombophilia on the Extent of Portal Vein Thrombosis at Diagnosis
1570	Fatih Işık	Gadoxetic Acid–Enhanced MRI Parameters for Functional and Volumetric Assessment in Chronic Liver Disease Stratification
1571	Yuhao Su	Impact of Hepatitis B Virus Infection on Surgical Conversion and Survival in Unresectable Hepatocellular Carcinoma Treated With TACE, Targeted Therapy, and PD-1 Inhibitors
1572	Ao Chen	Comparison of Long-term Efficacy and Renal Safety between Entecavir and Tenofovir Alafenamide Fumarate in Treatment-naive Patients with Chronic Hepatitis B
1574	zhen cai	Aeromonas Infections in Hepatic Hospital: Source-Specific Distribution and Antimicrobial Resistance Profiles Over Two Decades
1575	DEBBY GRACE JARDIOLIN	Metastatic Hepatic Pleomorphic Liposarcoma with Ruptured vascular mass: A case report
1577	Mingyue Ma	Long-Term HBsAg Kinetics and Prognostic Significant in Patients with Compensated Cirrhosis: A 13-year Prospective Cohort on Entecavir Therapy
1578	Zelu Meng	Construction of a Predictive Model for Adverse Outcomes in Patients with Acute Decompensated Cirrhosis Based on PBMC Transcriptomic Analysis
1579	Ye Rim Kim	Comparative Outcomes of Subsequent-Line Therapies Following First-Line Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in a High-Volume Korean Center
1582	jianing wang	Proteomic Profiling and Clinical Correlation of Prognostic Proteins in Advanced Hepatocellular Carcinoma with Hyperbilirubinemia
1583	Abhishek Lal	Effect Of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy In Patients With Liver Cirrhosis: A Randomized Clinical Trial (PEG-HE Trial)
1584	Yanjie Lin	Drug-related hepatic steatosis associated with antineoplastic drugs: A pharmacovigilance study from the FDA adverse event reporting system (FAERS)
1585	Xuemei Zhang	20(s)-ginsenoside Rg3 inhibits hepatocellular carcinoma via akkermansia-driven regulation of intestinal microbiota and bile acid metabolism
1586	jianing wang	Construction and validation of a nomogram for predicting survival in hepatocellular carcinoma patients with hyperbilirubinemia receiving targeted immunotherapy
1590	Ning Wang	Decoding the Genetic Overlap: A Pathway to Early Diagnosis of AKI in Cirrhotic Patients
1591	Eman Abdelsameea	Circulating Hypermethylated RASSF1A as a Possible Marker of Hepatocellular Carcinoma in Chronic HCV patients
1593	Man Li	Geniposide alleviates ALD by reducing CXCR2+neutrophil infiltration through inhibiting FKBP5/CXCL1 signaling pathway
1594	Han Ah Lee	A machine learning model for predicting hepatocellular carcinoma in patients with MASLD
1595	Xuejie Zhang	Development and validation of a non-invasive model for predicting advanced liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease and dysglycemia
1597	Minghui Li	Glycyrrhizin Preparations in Liver Diseases: A Systematic Review of Mechanisms and Therapeutic Potential
1599	Aymane Souili	Budd-Chiari Syndrome and Predictive Factors for Recanalization
1600	Wen Hui Lim	Liver Fibrosis Activity on MRI (cT1) Predicts Incident Neurological Events Independent of Brain MRI Metrics in the UK Biobank
1601	Muhammad Fahad Zakir	Interventional outcome of Endoscopic retrograde cholangio-pancreatography versus Percutaneous transhepatic cholangiography in malignant billiary strictures
1604	Darren Tan	Liver MRI Biomarkers of Fibro-inflammation and Steatosis Predict Long-term Liver Outcomes and Mortality in the General Population
1605	Conglin Zhao	Clinical Characteristics and Epidemiological Features of Hepatitis E Virus Infection Among People Living with HIV in Shanghai, China
1606	Chaoqian Huang	Marked HBsAb elevation in anti-HBc-positive cancer patients receiving PD-1 inhibitors: two case reports and literature review
1610	Xiaojing Wang	STING Aggravates Liver Fibrosis in Chronic hepatitis B concurrent with Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Gut Microbiota and Inducing Macrophage-Derived Lysozyme Expression
1611	Mengjiao Xu	Irreversible Electroporation (NanoKnife) in the Management of Refractory Recurrent Hepatocellular Carcinoma: A Systematic Review of Diagnostic and Therapeutic Advances

Paper No	Presenter	Title
1612	Shuoshuo Ma	Kuan-Sin-Yin potentiates PD1 blockade in hepatocellular carcinoma by enhancing B cell derived Granzyme B mediated apoptosis
1613	Chao Ma	History of Abdominal Surgery and of Treatment for Esophagogastric Varices Are Risk Factors for Portal Vein Thrombosis in Patients with Cirrhosis
1614	Zehra İkbal Karabal	Autoimmune hemolytic anemia complicated by portal vein thrombosis in a pediatric liver transplant recipient
1616	Shiyan Chen	SNX10 Promotes Lipid Accumulation in Hepatocytes by Inhibiting Autophagic Flux
1617	Anmol Anmol	Impact of post Kasai steroid-based protocol in Biliary Atresia: Real World Data From India
1618	Shiyu Wang	Optimizing Nucleos(t)ide Analogs Combined Peg-IFNα Regimen for CHB with Low-Level Viremia: Efficacy and Predictors
1620	Minghui Li Li	Precision Treatment and Frontier Advances of Glycyrrhizin Preparations in Drug-Induced Liver Injury
1621	YANUO CHEN	Establishment and assessment of a nomogram for predicting hepatic parasites disease
1622	Jianyun Wang	Impact of Tuberculosis Co‑infection on All‑Cause Mortality in Patients with Viral Hepatitis: A Propensity Score‑Matched Retrospective Study
1623	Chunfeng Mei	Molecular Association of Circadian Rhythm and Tryptophan Metabolism Pathway in the Pathogenesis of Chronic Hepatitis B
1626	Siqi Sun	Baseline Gut Microbiota Signatures Associated with Interferon Response and Functional Cure in Chronic Hepatitis B
1627	chaimaa ELMAJOUDI	Clinical and Serological Predictors of Virological Response to Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B: A 7-Year Cohort Study
1628	Qianqian Wang	A Prospective Study on a Group Mindfulness-Based Intervention for Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: Effects on Liver Steatosis and Psychological Symptoms
1630	YANUO CHEN	The effect of hepatic steatosis on the efficacy of immune-based integrative treatment for viral HCC
1631	Jian-Hong Zhong	Noninvasive preoperative prediction of major pathological response in unresectable hepatocellular carcinoma treated with conversion therapy using a clinical-CT radiomic model: a multicenter, retrospective study
1632	Yue Kong	Predictive Value of INR and DBIL for Short-Term Prognosis after the First Artificial Liver Support System Treatment in Patients with Acute-on-Chronic Liver Failure
1633	chaimaa ELMAJOUDI	MVPS and Thrombophilic Abnormalities as Leading Causes of Non-Tumoral Portal Vein Thrombosis: Epidemiological and Evolutionary Insights from a Cohort of 83 Patients
1635	Rajae BELHOCINE	Predictors of Incomplete Biochemical Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: Insights from a Moroccan Cohort
1636	Imane EL Mouatamid	Metabolic Dysfunction–Associated Steatotic Liver Disease in Normal-Weight Individuals: Clinical, Biological, Fibrosis, and Autoimmune Profiles in a Moroccan Cohort
1637	Jing Lai	The impact of serum lipids metabolism on the prognosis of hepatitis B virus related acute-on-chronic liver failure
1638	Lu Li	Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway
1639	Yu Zhang	TRPV4 Cooperates with HBx to Promote HBV Replication Through a Calcium-Mediated Positive Feedback Loop
1643	Jessica Kristy Quiza	PREDICTIVE SCORING MODEL FOR HEPATOCELLULAR CARCINOMA AMONG FILIPINO PATIENTS: A 10-YEAR RETROSPECTIVE STUDY
1644	Rajae BELHOCINE	Epidemiological, Clinical, and Therapeutic Profile of Chronic Hepatitis B in a North African Cohort: Determinants of Advanced Fibrosis
1645	Violeta Molagic	The dynamic of APRI and FIB-4 scores over a 10 year period in HCV cirrhotic patients after virological cure with direct-acting antivirals therapy
1648	Ouafae Dahri	Predictive factors of complications and treatment response in patients with autoimmune hepatitis: A 8-Year Single-Center Study
1650	Pravinkumar Rejliwal	A Pilot Study on Hepatitis B Core Related Antigen (HBcrAg) as a Novel Marker for Monitoring Antiviral Therapy in Chronic Hepatitis B Patients
1651	Anca Saran	The dynamic of alpha-fetoprotein in patients with hepatitis C cirrhosis after direct-acting antivirals therapy over a 10 year period
1654	SELMA TOSUN	Long-Term Prognosis of Acute HBV Cases
1655	Yingying Zhao	Alcoholic Liver Disease with Sarcopenia: Association with Increased Fall Risk and Impaired Activity of Daily Living
1657	Han Shi	Research on gut microbiota characteristics of PBC patients at different ALBI grades based on machine learning
1658	Chaoqian Huang	Exploring Factors Influencing Public Intention to Receive Hepatitis E Vaccination Based on the Theory of Planned Behavior
1659	Menyao He	Efficacy Analysis of Prednisone Tablets Combined with Azathioprine in the Treatment of Autoimmune Hepatitis: A Single-Center Retrospective Cohort Study
1660	Lu Zhang	Four-Year Survival in Giant Hepatocellular Carcinoma: A Case Report on Long-Term Disease Control Following Multimodal Therapy
1663	Weihua Cao	Diagnostic prediction model of porto-sinusoidal vascular disease patients with gamma-glutamyl transferase elevation
1665	Yun-Wen Chen	ADAR2 Deficiency Ameliorates Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis in Mice
1666	Hasan Yılmaz	Diagnostic Performance of Non-Invasive Fibrosis Scores Compared with Liver Biopsy in Chronic Hepatitis B
1667	JATA SHANKAR KUMAR	Combination of carvedilol and variceal band ligation is superior to carvedilol alone in primary prophylaxis of variceal bleed in cirrhotics with high-risk varices: A randomized controlled trial
1668	Ismail Qarch	Metabolic Steatosis in Chronic Hepatitis B: High Prevalence but No Impact on Fibrosis or Antiviral Response in a Moroccan Cohort

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1669	Dr SOURAV KUMAR SAHA sabuj	"Serum Prothrombin Induced by Vitamin K Antagonist-II (PIVKA-II) Biomarker in diagnosis of Hepatocellular Carcinoma"
1670	SELMA TOSUN	Evaluation of anti-HBs titers in children who received vaccine + HBIG at birth because their mothers were HBsAg positive in subsequent years
1671	Dr.Kartik Chaudhary	“Bitter Remedy, Bitter Consequence”: Mahogany Seeds Causing Herb-Induced Liver Injury
1674	Dr.Kartik Chaudhary	CMV Hepatitis Masquerading as Prolonged Cholestatic Phase of Hepatitis A
1675	Mohamed Abdel-Samiee	Magnitude of Clostridium Difficile Infection in Hospitalized Egyptian Cirrhotic Patients
1678	Xiaoxuan Liu	Identification and validation of cuproptosis-related genes for early warning of acute liver failure
1680	Mohamad Jamalinia	Artificial Intelligence Predicts Sex-Specific Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease
1682	ECE DEMİRKIRKAN	AWARENESS OF HEPATITIS B VIRUS REACTIVATION AMONG PHYSICIANS MANAGING PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY: A CROSS-SECTIONAL STUDY OF 150 PHYSICIANS
1683	Chaima Hsain	Hepatic Steatosis Beyond Fat: A Clinical, Anthropometric and Metabolic Exploration of an At-Risk Population
1684	Elizabeth Shumbayawonda	Patient-reported health is decreased in high-risk MASH defined by noninvasive biomarkers of fibro-inflammation in Japanese Adults
1685	Chaima Hsain	Chronic Portal Vein Thrombosis and Risk of Decompensation: Experience of a Moroccan Center
1686	Zehra İkbal Karabal	Preoperative volume estimation versus actual graft weight in living donor liver transplantation: a retrospective analysis
1687	Keyur Patel	Validation of Agile 3+ and Agile 4 for MASLD with advanced fibrosis and cirrhosis in a Canadian cohort
1688	SELMA TOSUN	Evaluation of HBsAg, anti-HBcIgG, anti-HBs, and anti-HCV test results for individuals who visited primary-level Family Health Centers (12 years of data covering the province of İzmir and its districts)
1689	Hakan Demiröz	Rapidly Progressive Acute Liver Failure Caused by Infiltrative Hepatic Amyloidosis: A Case Report
1691	Atiye Ayrık Demir	Effects of biological agents on hepatitis B virus reactivation in patients who are negative for hepatitis B surface antigen and positive for antibodies against hepatitis B core antigen
1692	Hamza Benazzouz	Fibrosis Regression Patterns in Chronic Hepatitis B: Evidence from Longitudinal Non-Invasive Biomarkers
1693	Meriem Amine	Evaluation of Artificial Intelligence in Clinical Decision Support: Application to Chronic Hepatitis B Cases According to the 2025 EASL Guidelines
1695	Meriem Amine	CHATGPT FOR PATIENT QUESTIONS ABOUT CIRRHOSIS: USEFUL BUT NOT INFALLIBLE
1696	Rajaa Boukhraiss	Characterizing Primary Biliary Cholangitis in Men: Clinical, Biological and Histological Profile
1697	Won Sohn	Combined use of fibrate and statin to reduce the risk of hepatocellular carcinoma: a population-based cohort study
1699	Meriem Amine	Endoscopic Management of Complications from Ruptured Hepatic Hydatid Cysts into the Bile Ducts
1700	Jaouhara Lahsini	Artificial intelligence-based prediction of ursodeoxycholic acid response in primary biliary cholangitis: comparison of two large language models
1701	Jaouhara Lahsini	Seronegative primary biliary cholangitis: clinical, biochemical and histological profile with comparison to seropositive disease
1702	Weihua Cao	Combining Interferon-α and Nucleos(t)ide Analogues to Enhance Early Virological Response in Chronic Hepatitis B
1703	Gülce Eylül Aldemir	First Case Report of Tenofovir Disoproxil Fumarate-Induced Perichondritis: A Case Study from the Perspective of Seronegative Autoimmune Processes
1704	Linmei Yao	Case Report of Hematopoietic Disorder Complicated by Severe Liver Injury: Clinical Features and Mechanistic Insights into the Co-occurrence of Hemophagocytic Syndrome and Aplastic Anemia
1705	Rui Zhao	Development of a Novel Animal Model for Acute-on-chronic liver failure (ACLF) in Metabolic dysfunction-associated steatotic liver disease: Confirmed the progression to ACLF in a non-cirrhotic liver disease stage
1706	Man Li #	Bushen granule plus entecavir improved the effectiveness for HBeAg negative chronic hepatitis B: A multicenter, randomized, double-blind, placebo-controlled clinical trial
1707	Taolong Zhou	Analysis of Risk Factors and Fibrosis Severity in Type 2 Diabetic Patients with Metabolic Associated Fatty Liver Disease: A Cross-Sectional Study
1709	Kyoung A Ko	Neck circumference and the risk of metabolic dysfunction-associated steatotic liver disease in non-obese individuals without visceral obesity
1710	Qiang Zhu	Mn-Tannic Acid Immunomodulators Potentiate PDGFRβ CAR-T Cell Function Through Enhanced proliferation for Synergistic Anti-Hepatic Fibrosis Therapy
1711	Man Li	Rougan Formula Alleviates Liver Fibrosis by Suppressing Macrophage Glycolysis via Downregulation of the Tenascin-C / HIF-1α / PFKFB3 Pathway
1712	Yanzhi Duan	Implementation of a Bidirectional Protection Model for Infection Control in a Dedicated Chronic Hepatitis B Outpatient Clinic: A Comprehensive Approach to Break the Chain of Bloodborne Transmission
1714	Yeongseok Hwang	Development and External Validation of Machine Learning-Based Prognostic Model for Liver Transplant Patients with HCC
1716	Federico Peralta	Hemoperitoneum as Initial Presentation of Hepatocellular Carcinoma in Chronic Hepatitis C: A Case Report

Paper No	Presenter	Title
1718	Mengfei Liu	Pediatric MASLD prevalence in the NHANES from 2017 to 2020 and the role of aging-related factors
1719	Wei Wang	Real-world Analysis of HBV pgRNA Dynamics and Its Correlation with Conventional Markers in CHB Management
1720	Yue Chen	Integrated experimental and transcriptomic analyses reveal the therapeutic mechanisms of the herbal formula WenQingYin against intrahepatic cholangiocarcinoma
1721	Yinzhong Shen	Longitudinal Changes in Fibrosis Marker: Monitoring Fibrosis Progression in People with HIV and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Longitudinal Cohort Study
1723	Sarker Mohammad Sajjad Sajjad	Impact of empagliflozin on liver fibrosis in adults with type 2 diabetes and nonalcoholic steatohepatitis
1724	Indra Altankhuyag	Some biochemical characteristics among viral hepatitis associated HIV- positive people in Mongolia
1728	WEN GAO	T Lymphocyte Subsets Participate in the Pathogenesis of Primary Biliary Cholangitis
1730	heming huang	Histone deacetylase inhibitor givinostat attenuates metabolic dysfunction-associated steatotic hepatitis and liver fibrosis
1733	Xiangsha Kong	The ATP7B c.1543+40G>A Splice-Site Variant was Confirmed as Pathogenic through Familial Segregation Analysis in the Genetic Diagnosis of Wilson Disease
1734	Zitian Ren	Diminished protection of Vitamin E in pediatric MASLD with lipid disorder: findings from a national wide survey
1736	Sung Won Lee	An Increase in Regulatory B Cells and a Reduction in T Helper 17 Cells Play a Crucial Role in Achieving Tolerance in Liver Transplantation
1737	Shin-Yu Tsai	Prognostic Impact of Cirrhosis in Patients with Hepatocellular Carcinoma and Concurrent MASLD Undergoing Surgical Resection
1741	Mohit Varshney	Alcohol-Use–Related Outcomes Following Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcohol-Associated Hepatitis: A Secondary Analysis of a Randomized Controlled Trial
1742	Young Mi Hong	Pretreatment neutrophil-to-Lymphocyte Ratio as a Predictive Marker for Tumor Response to Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma: A Multicenter Retrospective Study
1743	Hwa Young Choi	Area deprivation and hepatitis C infection in Korea: A multilevel analysis, 2005-2020
1744	Ji Hoon Kim	Proteomics Biomarker for Predicting Responders to Atezolizumab and Bevacizumab Therapy in Hepatocellular Carcinoma
1745	NATHANIEL CAMANGON	Flare to Failure: Hemoadsorption Therapy for Acute-on-Chronic Liver Failure in Chronic Hepatitis B Infection Unmasked During Antikoch's Therapy
1746	Eunho Choi	Decision Tree model using Exosomes to Predict Favorable Outcome of Atezolizumab and Bevacizumab Combination Therapy in Hepatocellular Carcinoma
1748	Suwen Jiang	Analysis on the differences of clinicopathological characteristics in drug-induced liver injury patients with positive or negative autoantibodies and different clinical types
1749	In Hee Kim	Seroprevalence and Epidemiological Features of Hepatitis E Virus Infection in South Korea: Analysis of KNHANES Serum Samples
1752	Yingxin Sun	Exploring the Associations of Liver PDFF with Mortality and Disease Incidence: A Prospective Study in the UK Biobank
1755	WEN GAO	Role of IL-16 in autoimmune hepatitis
1756	Lifu Zhu	Recombinant human thrombopoietin promotes platelet recovery in hepatocellular carcinoma patients receiving interventional therapy combined with targeted and immunotherapy (SYNERGY-TPOACT): a retrospective cohort study
1759	Yawen Wang	Value of Preoperative Contrast-Enhanced CT-based Radiomics for Predicting CK19-Positive Hepatocellular Carcinoma
1760	Young Eun Chon	Comparison of effectiveness between phentermine/topiramate and liraglutide in obese patients with metabolic dysfunction-associated steatotic liver disease
1761	Yuanying Zhao	Expression of ALOX15 in the Development and Reversal of Liver Fibrosis and Its Effects on Macrophage Inflammatory Cytokine Secretion
1762	Jason Phowira	From Liver to Spine: Spinal Metastatic Compression as the Initial Manifestation of Hepatocellular Carcinoma
1763	Udit Vaish	Cirrhosis in Transition: Rapid Metabolic and Alcoholic Rise with Declining Viral Burden in an Indian Tertiary Center
1764	Edzil Marice Forteza	Multidisciplinary management of diffuse intraductal papillary neoplasm of the bile duct in an elderly patient with limited therapeutic options
1765	MOHD. IBRAHIM KHAN	Synergistic Hepatoprotection via SREBP-1c/PPAR-α, FXR/CYP7A1, and Insulin Signaling Modulation by Empagliflozin and Cholestyramine in STZ induced diabetic rats
1766	Yaxin Li	Association Between Baseline Hepatic Nodules and Their 3-Month Dynamic Changes with Hepatocellular Carcinoma Risk in HBV Cirrhosis Patients on Antiviral Therapy
1767	Chan Joong Bae	Comparison of Treatment Efficacy and Safety Profile of Atezolizumab Plus Bevacizumab in BCLC B and C Patients with Hepatocellular Carcinoma
1770	Hye Seon Kim	Serum HBV Markers Reflect Intrahepatic cccDNA and Transcriptional Activity in a Phase-Dependent Manner in Chronic HBV Infection
1772	Rosmy Babu	HLA Variants and Oral Microbiome Signatures Associated with Antibody-Mediated Rejection Post Living Donor Liver Transplantation
1773	Zixin FENG	Siwu Decoction Inhibits Hepatocellular Carcinoma via Tumor Necroptosis-Induced Suppression of Myeloid-Derived Suppressor Cells
1774	Xiaofang Peng	An Innovative, Integrated "Screen-to-Treat" Model with a Three-Tier Network Significantly Enhances Viral Hepatitis Screening Efficiency and Linkage to Care in Zhuhai, China: A Comparative Study

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1777	Ke Yin	Metabolic Dysfunction, Particularly Diabetes, Accelerates Liver Disease Progression in Chronic Hepatitis B
1778	Enoka Gonsalkorala	Cirrhosis and low-fibrosis MASLD driving demand for outpatient hepatology services at a large Australian quaternary referral centre
1780	Soner KARABULUT	NHSL3 Knockout Enhances Sorafenib Sensitivity by Promoting G1 Phase Accumulation in Huh-7 Hepatocellular Carcinoma Cells
1784	Dr. Asma Shabbir	Whole Exome Sequencing Identifies PNPLA3 and Rare ABCC8 Variants as Genetic Risk Factors for Metabolic Dysfunction–Associated Steatotic Liver Disease in South Asians
1786	Kyung-Ah Kim	Environmental Risk Factors and Comorbidity Profiles Associated With Autoimmune Hepatitis in Korea: A Nationwide Case–Control Study
1787	Minghui Li	Metagenomic Study on Adult Cases of Hepatitis of Unknown Etiology: No Consistent Novel Pathogen Identified Amidst Highly Heterogeneous Viral Communities
1788	Yu Zhao	Yinchenhao Decoction Suppresses Metabolic Associated Fatty Liver Disease Inflammatory Injury by Regulating Monocyte Superoxide Metabolism
1789	Zhuoru Jiang	Correlation Between Liver Stiffness and Cognition in MASLD Patients Based on MRE and Neurovascular Coupling Assessment
1790	Nikhil Nagre	Prognostic utility of the Ammonia-to-ULN ratio (AMM-ULN) for predicting 28-day mortality and liver related complications in hospitalized patients with decompensated cirrhosis.
1791	Bonnie Chun Kwan Wong	Formulation of the second viral hepatitis action plan in Hong Kong: carrying forward the achievements for final push towards elimination
1792	Emerald T. Gersava	Undiagnosed Metastatic Hepatocellular Carcinoma presenting as Breast Mass in an Adult Male: A Case Report
1793	Qinglei Zeng	Effectiveness and Safety of 96-Week Tenofovir Amibufenamide in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Real-World Study
1794	Deepika Singh	Ferulic acid-loaded liposomes mitigate Hepatic Ischemia-Reperfusion Injury in a rat model associated with Liver Transplantation via altering apoptosis, mitochondrial function and TLR-4/NF-B/NLRP3 inflammatory pathway
1795	Emerald T. Gersava	Turning the Tide: Successful Management of a Complicated Case of Acute-on-Chronic Liver Failure with Double Plasma Molecular Adsorption System
1796	Deepika Singh	A novel flavonoid Galangin modulates hepatic ischemia–reperfusion injury and regulates TLR-4/NF-κB/NLRP3 inflammatory pathway following orthotopic liver tranplants in rat models.
1797	Naoyuki Fujimori	Stellate Cell–Derived Complement Component 7 as a Determinant of Fibrosis Progression and Liver-Related Events in MASLD: An Integrated Multi-Omics Study
1801	Tae Seop Lim	Fibrotic Burden in Metabolic Dysfunction-associated Steatotic Liver Disease Identifies Cardiovascular and Mortality Risk in Type 2 Diabetes
1807	Ashok Raj	Increased risk of decompensation in patients with clinically significant portal hypertension awaiting endoscopic variceal screening - a metropolitan Australian study
1808	Xinhua Ren	Overshadowed by Immunotherapy: Unmasking Chemotherapy-Related Hepatic Vascular Injury (SOS-Pattern) and Managing Catastrophic Hemorrhage
1809	Wenyue Wu	Transcriptomic Deconvolution Characterizes Intrahepatic Neutrophils in On-treatment Chronic Hepatitis B Patients with Liver Fibrosis
1810	Miaomiao Tian	Regulatory Mechanism of EEF2 lactylation in Calcium Homeostasis Dysregulation of MASLD Hepatocytes
1811	TA FUXIA TA	Combination with glucocorticoids during artificial liver support system treatment does not improve the survival rate of Acute-on-chronic liver failure patients: A retrospective cohort study
1814	Seong Kyun Na	Weight Reduction and Its Association With CAP and Liver Stiffness in MASLD
1817	TA FUXIA TA	Comparison between Plasma Exchange and Dual plasma molecular adsorption system combined with Plasma Exchange on Acute-on-Chronic Liver Failure: A retrospective cohort study
1823	Huihui Lu	Study on Risk Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Interferon
1826	Xinyue Ma	Primary biliary cholangitis with concomitant fatty liver disease: a reappraisal of clinical features, UDCA treatment response, and prognostic implications
1827	Nadeem Sheikh	Identification of Ferroptosis-Related Biomarkers and Hub Genes in Non-Alcoholic Fatty Liver; an <i>In Silico<i> Transcriptomic Analysis
1828	Gülnur Kul	Association of CORE Score with Parenchymal Liver Disease in HBsAg-Positive Patients
1829	Linhui Hu	Clinical Challenges in Diagnosing Primary Testicular Lymphoma: Report of Two Cases in Elderly Patients
1830	Nadeem Sheikh	Integrative Analysis of Differentially Expressed Ferroptosis-Related Genes in Cell-Cycle Regulation of Hepatocellular Carcinoma
1831	Elif Cadirci	Effect of epigallocatechin gallate on ochratoxin induced liver damage
1833	Adrian Dominik	Multifunctional Dialysate for Renal, Hepatic, and Pulmonary Support
1835	Nadeem Sheikh	Meta-Analysis of Ferroptosis-Related Differentially Expressed Genes in Hepatocellular Carcinoma
1838	Huihui Lu	Predictive Value of the aMAP Score for Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated with Interferon
1839	Ayush Jasrotia	Efficacy of long term albumin therapy in the treatment of decompensated cirrhosis.
1840	Pengxuan Wu	Severe Hepatic Steatosis Attenuates Response to PEG-IFN alpha-2b in HBsAg Clearance-Favorable Chronic Hepatitis B Patients: A Retrospective Cohort Study
1841	Hee Bok Chae	Timing of endoscopic hemostasis does not affect the short-term outcomes in acute variceal bleeding in liver cirrhosis patients.

Paper No	Presenter	Title
1842	Long Xu	T-MSCs Alleviate Autoimmune Hepatitis in a ConA Mouse Model by Inhibiting IL-21–Driven Inflammatory Responses
1844	YIJING ZHANG	Yunpilishi Formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting tPA
1845	Zhao Chen	Inositol Hexaphosphate Prevent WD/CCl₄-Induced Metabolic Dysfunction-Associated Steatohepatitis in Mice
1847	Yaqin Zhang	The Clinical Significance and Optimization Strategies of HBeAg Seroclearance in Chronic Hepatitis B Treatment
1850	Jeremie Manarang	Curative Outcome in Hepatocellular Carcinoma: A Case Report on Complete Pathologic Response After Multimodal Therapy
1852	Christine Velasquez	Navigating Vascular Complexity: Successful Locoregional Treatment of HCC with a Hepatic Arterioportal Fistula
1853	Anh Nguyen Thi Van	Surgical Site Infections Following Hepatectomy and Associated Risk Factors in a Tertiary Liver Surgery Center
1854	Zyrah Lou Samar	Cross-Border Collaboration in Primary Sclerosing Cholangitis: A Landmark Living Donor Liver Transplant by Makati Medical Center (Philippines) and Asan Medical Center (Korea)
1855	Siqi Zhang	Genotype-Phenotype Correlation of ATP7B Mutations in Wilson Disease
1856	Dinh Thang Nguyen	THE VALUE OF ALBI AND ALBI-PLT SCORE IN PREDICTING ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS
1858	Hongxiao Hao	Analysis of risk factors for portal hypertension in early histological primary biliary cholangitis
1859	Christine Velasquez	Unmasking Hepatic Tuberculosis: A Case Series on Its Hepatobiliary Mimicry, Diagnostic Hurdles, and Management Challenges
1860	Cleo Christille Lynn Lom-oc	The Great Imitator in the Liver: A Case of Syphilitic Hepatitis Presenting as Cholestatic Jaundice
1862	Siqi Zhang	Radiomics-Based Skeletal Muscle Model at L3 for Predicting 90-Day Mortality in Acute-on-Chronic Liver Failure: Superior to MELD Score
1863	Haoyu Wen	Differentiating acute-onset autoimmune hepatitis from drug-induced autoimmune-like hepatitis: a multicenter study and score development
1864	Christine Velasquez	HONEYCOMBED LIVER: HEPATIC MELIOIDOSIS, A RARE MIMICKER OF PYOGENIC ABSCESS IN A NON-EXPOSED, DIABETIC PATIENT
1865	BETTYNA ROSE RUSTIA	Biliary Mass Mimicking Cholangiocarcinoma as a presentation of Hepatobiliary Tuberculosis in a Young and Immunocompetent patient.
1866	Cristina Coll-Ortega	Real-world evidence on albumin use in the management of patients with cirrhosis and ascites during paracentesis in Taiwan
1868	Christine Velasquez	Phenobarbital-Induced DRESS with Acute Liver Injury: A Hepatology-Focused Approach Using Early Immunosuppression and Hepatoprotective Support
1869	Atsushi Tanaka	Societal impact of cholestatic pruritus in patients diagnosed with primary biliary cholangitis: A cross-sectional survey in Japan
1870	Desiree Jane Lacuin	SILENT STONES SERIOUS INFECTION: THE ROLE OF ASYMPTOMATIC CHOLELITHIASIS IN PYOGENIC LIVER ABSCESS
1871	Christine Velasquez	ORAL SEMAGLUTIDE FOR WEIGHT MANAGEMENT AND GASTROINTESTINAL SAFETY IN METABOLIC DISEASE; A META-ANALYSIS AND NARRATIVE LIVER OUTCOME SYNTHESIS
1872	Fengge Zhu	Circulating C1Q+ monocytes associate with lower HBsAg level in chronic HBV infection
1873	Qing-Lei Zeng	The Clinical Epidemiology and Treatment of Acute Hepatitis C Caused by Unsafe Clinical Practices
1874	Yadi Li	Research on the Mechanism of LSEC Functional Abnormalities Induced by TMAO in porto-sinusoidal vascular disease
1875	Tianyi Xia	Circulating NCAN as a protective biomarker and causal modifier of multistage liver disease
1876	John Paul Dela Peña	Beyond the Usual Course: Prolonged Cholestatic Hepatitis A in a 36-Year-Old Female
1877	Luqi Tang	Dynamic Increase in HBsAg during Long-Term Antiviral Therapy: The Role of HBV Integration and Clonal Hepatocyte Expansion
1878	Xuanxuan niu	Association between the alkaline phosphatase-to-albumin ratio and all-cause mortality in critically ill patients with cirrhosis and sepsis: a retrospective study
1879	Desiree Jane Lacuin	PRIMARY MYELOFIBROSIS PRESENTING WITH VARICEAL BLEEDING: A RARE CAUSE OF NON-CIRRHOTIC PORTAL HYPERTENSION
1880	YuYu Li	The predictive value of different attenuation assessment tools for clinical adverse outcomes in patients with cirrhosis
1881	Hyunwoo Oh	Serum free T3/ free T4 ratio as a predisposing factor for the development of metabolic dysfunction-associated steatotic liver disease: a large-scaled cohort study of euthyroid state
1882	Qing-Lei Zeng	Safety and Effectiveness of Peginterferon Alfa-2b Combined with Tenofovir Amibufenamide in Patients with Chronic Hepatitis B
1884	Ajay Aravind	Variceal bleeding in toddlers: Is the endoscopic outcome in extrahepatic portal hypertension worse than chronic liver disease?
1885	Alexey Goncharov	The sweet protein brazzein in ice cream suppresses postprandial glucose elevation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes mellitus (DM).
1887	Jing Lai	Dynamic changes of serum lipids metabolism in hepatitis B virus related acute-on-chronic liver failure
1888	Liang Peng	An Optimized In-Hospital Management Model Enhances Linkage to Care for Non-Hepatology HBV-Infected Patients: Interim Analysis of Hot Wave Project 2.0
1891	shihao Guo	Research progress on the association between metabolic dysfunction-associated fatty liver disease and gallstones
1892	BETTYNA ROSE RUSTIA	Reactive Pericarditis Secondary to Cholangitic Abscess from a Neglected Biliary Stent: A Case Report

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1894	Huiyang Fan	AI-Driven Pathomics: Transforming Precision Medicine Across the Chronic Liver Disease-Hepatocellular Carcinoma Spectrum
1896	Menyao He	Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital
1898	Lu Ziman Lu	Successful Management of Hepatitis B Virus Reactivation-Induced Acute-on-Chronic Liver Failure with Integrated Traditional Chinese and Western Medicine: A Case Report
1900	Abhishek Lal	Prevalence of Hepatitis B and C among Adolescents and Young Adults in Sindh, Pakistan: A Substudy of a Provincial Population-Based Survey
1901	Jiaqi Li	A Modular Assembly of Urine-Derived Stem Cells and Hydrogel into a Therapeutic Ectopic Mini-Liver for Wilson's Disease
1902	Mengya Liu	Antiviral Therapy Leads to Virological Response and Functional Cure in Treatment-Naïve Indeterminate-Phase Chronic Hepatitis B with Normal ALT
1904	Abhishek Lal	High prevalence of Hepatic Steatosis in adolescence and Young Adults A crossectional survey from Sindh Pakistan
1905	Rafael Emmanuel Mendoza	Partial Splenic Embolization in a Cirrhotic Patient with Refractory Variceal Bleeding and Portal Venous Thrombosis
1907	Tushar Prabhakar	Delayed diagnosis of intrahepatic cholestasis of pregnancy in North India: Uncovering health-system gaps through a mixed-methods approach
1910	Hezhao Wang	A Bibliometric Analysis of the Diagnosis and Treatment of Portal Hypertension Based on the Web of Science Database
1913	Bolor Beejin	Impact of of air pollution to liver diseases
1914	shihao Guo	Research progress on the association between metabolic dysfunction-associated fatty liver disease and gallstones
1915	SELMA TOSUN	Ibrutinib-Associated HBV Reactivation in Hematologic Malignancies: Clinical Experience From Our Center
1917	Weihua Cao	Association between the platelet/high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease: A corhot study
1919	Kuo-Chih Tseng	Trends of Chronic Liver Disease and Cirrhosis Mortality in Medically Underserved Areas of Taiwan, 2015–2022
1921	Ajay Aravind	Clinical spectrum and long-term adverse outcome of Infantile onset Extrahepatic Portal Vein Obstruction
1922	Isabela-Daniela Staicu	Clinical and therapeutical characteristics of patients infected with hepatitis B and D viruses in a tertiary center from Bucharest, Romania
1924	Jan Stange	Safety and feasibility of next-generation extracorporeal albumin detoxification/-dialysis for long-term bridging to liver transplantation in secondary sclerosing cholangitis
1925	Saleh A. Alqahtani	Burden of metabolic dysfunction-associated steatotic liver disease in Saudi Arabia: Evidence from the first nationwide population-based cohort study
1927	Saleh A. Alqahtani	The severity of diabetes mellitus in metabolic dysfunction-associated steatotic liver disease in the Saudi population
1928	Basavaraj Patil	Beyond the usual suspects”: uncovering autoimmune hepatitis overlap with Wilson disease
1929	Wei Huang	hUC-MSC-Derived Exosomal miR-22-3p Attenuates Liver Fibrosis via Inhibition of the NLRP3 Inflammasome
1930	Ajay Aravind	Outcomes of Percutaneous Interventions in Liver Abscess in children: 15-year experience from a tertiary care center
1931	Nazan Tuna	Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients. A Multicenter Study From Türkiye
1932	Zhong wen Wang	Parkin perturbs Hepatocyte Mitochondria-associated Endoplasmic Reticulum Membranes Dynamics
1933	ikram aluahabi	Advancing Fibrosis Assessment in Chronic Hepatitis C Through Non-Invasive Approaches
1936	Imteaz Mahbub	Generalized Anxiety Among the patients of Fatty Liver Disease: A Cross Sectional Study
1937	Anmol Anmol	Evaluating Baveno-VII Recompensation in Children with Autoimmune Decompensated Cirrhosis: Clinical Predictors and Immune Axis Modulation
1939	Shadan AlMuhaidib	Transient elastography versus the fibrosis-4 index for fibrosis detection in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis
1942	BENGU TATAR	Long-term outcomes of chronic hepatitis B: Effect of metabolic risk factors on liver stiffness measurement by vibration controlled transient elastography
1944	Anmol Anmol	Baveno VII–Defined Hepatic Recompensation in Children with Decompensated Cirrhosis: Frequency and Determinants
1946	SELMA TOSUN	Comprehensive Assessment of HBV Reactivation in Immunosuppressed Hematology Patients: Serological and Clinical Perspectives
1947	SAMIA M'RABET	Hepatocellular Carcinoma: A Seven-Year Cohort Revealing Large Tumor Size and Advanced Fibrosis Despite Early BCLC Staging
1948	Saleh A. Alqahtani	Genetic and metabolic characteristics of metabolic dysfunction–associated steatotic liver disease in a pilot subset of a population-based cohort study in Saudi Arabia
1951	Sibel Yıldız	Clinical, Laboratory and Microbiological Profile of Post–ERCP Infections: A Retrospective Study from a Single Tertiary Referral Center
1952	Sena Nur Doğan	Performance of anti-HCV screening and identification of false-positive results in a real-life cohort
1953	Elif Cadirci	Chronic Dexamethasone Drives Selective SNAT Remodeling to Fuel HNF4-Alpha-Mediated Gluconeogenesis
1955	ALPER GÜNDÜZ	The overlooked Threat on the Path to Hepatitis B Eradication: Delta Hepatitis
1956	BENGU TATAR	Comparative Evaluation of Serological, Virological, and Biochemical Outcomes in Chronic Hepatitis B Patients Receiving Tenofovir or Entecavir

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
1957	Jiayi Wang	HBx Upregulates the Interferon Negative Regulator IFITM2 via Activating the JAK-STAT Pathway and Impairing Lysosomal Function
1958	Faisal Abaalkhail	Optimizing operator competency in transient elastography for metabolic dysfunction-associated steatotic liver disease screening in a multicenter study
1959	Elif Cadirci	Investigation of the Effects of Nintedanib in Liver Damage Induced by CCl4 in Rats
1960	Saleh A. Alqahtani	High risk of obstructive sleep apnea among adults with metabolic dysfunction-associated steatotic liver disease based on findings from a national population study
1961	Ebru Taşpınar Şen	HBV Reactivation in Rheumatology Patients With Resolved Hepatitis B Infection Receiving DMARD Therapy
1962	Akash Nair	Native liver survival in pediatric hyperacute liver failure: Is standard medical therapy effective ?
1963	Sabahat Çeken	Hepatitit B Screening Prior to Immunosupresive Therapy in Patients with Multiple Myeloma
1964	Akash Nair	Nephropathy Following Portosystemic Shunt Surgery in Children with Extrahepatic Portal Venous Obstruction: A hitherto undescribed entity
1966	Alara Apa	Investigating hepatitis B virus recurrence in post-liver transplant patients: a single-center retrospective cohort study
1969	Saleh A Alqahtani	Patients with Hepatocellular Carcinoma Undergoing Transarterial Therapies Have Higher Risk of Hepatic Decompensation With Transarterial Radioembolization and Are Linked to Worse Prognosis
1970	Saleh A. Alqahtani	Impact of metabolic dysfunction-associated steatotic liver disease on health-related quality of life among adults in a national Saudi population study
1971	SELMA TOSUN	Evaluation of HBV screening status and test results for mothers, fathers, siblings, spouses, and children of individuals who are HBsAg positive
1972	TALAL KHURSHID BHATTI	Comparative Inpatient Outcomes and Comorbidity Profiles in Patients with Alcohol-Associated Liver Disease With and Without Metabolic Syndrome: Insights from a Nationally Representative US Database
1974	Elif Cadirci	Investigation of SNAT Gene Expression in Liver Tissue in an Experimental Diabetes Model
1975	Alfiyyah Rizqy	NTCP S267F (rs2296651) in HBV Infection Among Asian Populations: A Systematic Review and Meta-analysis
1976	Alexey Goncharov	Advanced liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) impairs sensory perception of ice cream with the protein sweetener brazzein
1977	Elkhashab Magdy	PREVALENCE OF LIVER FIBROSIS AMONG A COHORT OF PATIENTS WITH METABOLICALLY ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) FOLLEWED AT AN URBAN SETTING: IMPACT OF UTILIZATION OF FIBROSCAN.
1978	Saleh A Alqahtani	Clinical characteristics and one-year survival of patients with hepatocellular carcinoma linked to metabolic dysfunction-associated steatotic liver disease: findings from a comprehensive institutional registry
1979	Houda Chehboune	Squamous cell carcinoma of the gallbladder: A case report
1980	Elkhashab Magdy	SPLEEN STIFFNESS MEASUREMENT AS A FAVORABLE PREDICTOR OF PORTAL HYPERTENSION IN A COHORT OF PATIENTS WITH CHRONIC LIVER DISEASE FOLLOWED AT AN URBAN LIVER CENTRE IN TORONTO (TLC).
1981	Stine Koball	Improving Elimination in Albumin-Dialysis Liver Support: Different Responses of Water-Soluble and Albumin-Bound Toxins
1983	Yusuf Bünyamin Ketenci	Unmasking Cryptogenic Cirrhosis: Extreme Low LDL-C as a Critical Clue for Adult-Onset Familial Hypobetalipoproteinemia
1986	ُEman El-Ahwany	Polymeric Nanoparticle-Mediated Delivery of miR-221 as a Novel Therapeutic Approach for Hepatocellular Carcinoma
1987	Saleh A Alqahtani	The Economic and Health Burden of Liver Cancer in Saudi Arabia: An Analysis of Costs, Health Outcomes, and the Advantages of Early Detection
1988	yiheng tang	Research on Biomarkers of Liver Injury in Patients with Hepatocellular Carcinoma under Combined therapies Based on ICIs
1990	Jumshaid Qureshi	Description of a Cohort of patients with chronic Liver disease of various etiologies characterized by TEE (Fibroscan): Toronto Liver Centre (TLC)-Real-world experience.HIGH PREVELECE OF MASLD
1991	Saleh A. Alqahtani	Advances in early detection of hepatocellular carcinoma: a systematic review of novel diagnostic approaches
1992	Hatun Öztürk Çerik	Sustained Virologic Response After Only One Week of Glecaprevir/Pibrentasvir: A Rare Ultra-Short Treatment Success
1994	Atiye Ayrık Demir	Effects of biological agents on hepatitis B virus reactivation in patients who are negative for hepatitis B surface antigen and positive for antibodies against hepatitis B core antigen
1995	Ilya Abedi	Ethnic Variation in FibroScan-Detected Fibrosis and Steatosis in a Large Multi-Ethnic Canadian Cohort: Implications for Targeted MASLD Screening
1996	Yrah Damiene Fernandez	Triple Threat: A Rare Case of Drug-Induced Liver Injury Triggering Autoimmune Hepatitis and Overlapping Systemic Lupus Erythematosus
1997	Sang Min Yoon	Hepatic resection versus stereotactic body radiation therapy as first-line treatment for BCLC stage 0 hepatocellular carcinoma: a propensity score-weighted analysis
1998	JI HOON KIM	The Efficacy of Atezolizumab and Bevacizumab Combination in real world for Advanced Hepatocellular Carcinoma
1999	Fariba Yadolahi	Malnutrition and its association with mortality in liver cirrhosis: a prospective nutritional assessment in northern Iran
2001	Ning Han	Retrospective Analysis of Clinical and Genetic Characteristics in 68 Adult Patients with Gilbert Syndrome from a Tertiary Hospital in Southwest China

Paper No	Presenter	Title
2003	Wanxin Shi	Mechanism-Based Efficacy and Advantage of Traditional Chinese Medicine in Treating Anemia Associated with HBV-Related Hepatocellular Carcinoma from an Inflammatory Perspective
2005	SELMA TOSUN	The positive impact of the national HBV vaccination program implemented in Turkey on the prevalence of HBV among health school students
2007	Yanqin Du	A Survey on Awareness of Antiviral Therapy Among CHB Patients
2009	Yuerong Zhang	A research on gastroesophageal varices in patients with liver cirrhosis of different etiologies
2011	Xinhao Gao	Integrated Multi-omics Liquid Biopsy: Advancing Early Detection and Precision Management of HCC
2013	Saleh A Alqahtani	Projected health and economic impact of physical activity on metabolic dysfunction-associated steatotic liver disease in Saudi Arabia: A Markov modeling study
2014	Yinzhong Shen	Longitudinal Changes in Non-Invasive Fibrosis Markers and Risk Factors for Fibrosis Progression in People with HIV and Metabolic Dysfunction-Associated Steatotic Liver Disease
2015	Yuerong Zhang	A research on gastroesophageal varices in patients with liver cirrhosis of different etiologies
2016	Matthew Joseph Po	Comparing Protein Induced by Vitamin K Absence II and Alpha-Fetoprotein in Hepatocellular Carcinoma: Clinical and Tumor-Related Correlations in a Filipino Cohort
2017	Hwa Young Choi	The Cost Changes in Hepatitis C Patients Before and After the Introduction of Direct-Acting Antivirals in Korea
2020	Chengcheng Li	FOXK1 aggravates acute liver failure through HIF-1α-mediated histone lactylation at H4K16
2021	Xia Liu	Sex-related differences in clinical and immunologic phenotype of male primary biliary cholangitis: a retrospective cohort study
2022	Xin Wang	Xiaozhi Huaxian Formula Ameliorates Type 2 Diabetes-Associated Metabolic Dysfunction-Associated Steatohepatitis via the Gut-Derived Acetate–Hepatic GPR43 Axis
2024	Yuqing Zhao	Coronary heart disease is an independent risk factor for liver fibrosis progression in patients with MAFLD
2025	Fan’e Cheng	Targeting the Gut-Liver Axis Novel Strategies for Liver Cirrhosis Intervention
2026	Fan’e Cheng	A Bibliometric Analysis of Medicinal Food in Chronic Liver Disease Research
2030	ahmet uyanıkoğlu	İrritabl Bağırsak Sendromu Olan Reprodüktif Dönemdeki Kadınlarda Yaşam Kalitesinin Değerlendirilmesi
2031	Xinyu Zhao	Global Burden and Trends of Primary Liver Cancer Attributable to Comorbid Type 2 Diabetes Mellitus Among People Living with NASH: An Observational Trend Study from 1990 to 2021
2032	Fan’e Cheng	The Therapeutic Potential of Traditional Chinese Medicine in the Management of Chronic Hepatitis B
2033	Seung Up Kim	Risk stratification of chronic kidney disease using noninvasive tests in metabolic dysfunction-associated steatotic liver disease
2034	Vahe Azatyan	Pathomorphological characteristics of the marginal gingiva in patients with viral hepatitis B
2036	Xinyu Zhao	Targeting T-Cell Exhaustion in Chronic Hepatitis B: Therapeutic Potential and Mechanisms of Traditional Chinese Medicine and natural products
2037	Mohamed abdelmegeed ahmed	Assessment of hemoglobin A1c in hemodialysis patients with diabetes before and after erythropoietin treatment
2038	Mohamed Abd Elmaged Ahmed	Normal FIB-4 values do not exclude advanced fibrosis in Egyptian MASLD patients
2040	Hongxiao Hao	Analysis of Clinical Characteristics in Patients with Early-Stage Primary Biliary Cholangitis Complicated by Portal Hypertension
2042	Tatia Khachidze	Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease in the Adult Georgian Population: A Nationwide Multiregional Clinic-Based Study
2043	Tatsuo Kanda	Effects of immunosuppressants on HAV replication in human hepatoma cell lines
2044	Yuan-Hai Zhou	Spatiotemporal Changes in the Burden of Viral Hepatitis and the Influence of COVID-19 in China: A 20-Year Analysis
2046	wei lun tsai	Clinical Characteristics and Outcomes for Hepatocellular Carcinoma with Extrahepatic Metastases
2048	Sedat ÇİÇEK	INVESTIGATION OF THE RELATIONSHIP BETWEEN SUBCUTANEOUS AND VISERIAL FAT TISSUE MEASUREMENTS AND NON-INVASIVE FIBROSIS SCORES (FIB-4, APRI, AAR) IN THE EVALUATION OF LIVER DAMAGE ASSOCIATED WİTH CELIAC DISEASE
2049	Tatsuo Kanda	Zinc acetate enhances glucose-regulated protein 78 and anti-HAV activity of ribavirin in vitro
2050	Hien Chu Thi My	Long-term Outcomes of Tenofovir Therapy in Vietnamese Chronic Hepatitis B Patients: A 5-Year Retrospective Cohort Study
2051	Ladislav Spisak	PILOT STUDY ON LONG-TERM EFFECTIVENESS OF THE KARLOVY VARY THERMAL SPRING DRINKING CURE FOR MASLD
2052	Ahmet Uyanikoglu	A Young Patient Presenting With Hepatocelluler Carcinoma and Portal Vein Thrombosis Developing on A Backgraund of Non-Cirrhotic Hepatitis B: A Case Report
2054	Jonggi Choi	Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 Diabetes
2055	Gao Chen	Cost-Effectiveness Evaluation of Elmetenovir in the Treatment of Chronic Hepatitis B
2057	Gao Chen	Application Value of HBV RNA Quantitative Detection in Antiviral Treatment Monitoring for Chronic Hepatitis B Patients
2058	Gao Chen	Clinical Application Value of HBV RNA Detection in HBV DNA-Negative Chronic Hepatitis B Patients
2059	Gao Chen	Application Value of HBV RNA Detection in Assessing the Risk of Relapse After Discontinuation of Antiviral Treatment in Patients with Chronic Hepatitis B

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2060	Gao Chen	Efficacy and Safety of Tenofovir Amibufenamide in the Treatment of Elderly Patients with Chronic Hepatitis B and Liver Cirrhosis
2061	Gao Chen	Real-World Study of Tenofovir Amibufenamide in the Treatment of Hepatitis B-Related Liver Cirrhosis
2062	Kevin Rae Lumunsad	Clinical Significance of Prognostic Nutritional Index for Prognostication of Decompensated Liver Cirrhosis: A Retrospective Cohort Study
2063	Jiatu Zhong	Research Trends and Hotspots in Autoimmune Hepatitis: A Bibliometric Analysis
2064	Xiucheng Pan	Early Antibiotic Exposure Shortens Progression-Free Survival in Unresectable Intermediate-Advanced HCC Treated With ICI Plus TKI and TACE: A Propensity-Score Matched Study
2069	Yuhan Wang	Effects of Angelicae Sinensis Radix Combined with Paeoniae Radix Alba on Enterogenous Endotoxin and Hepatic Toll-like Receptor 4 Signaling Pathway in Mice with High-Fat Diet-induced Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2070	Zhambyl Ospan	THE USE OF A MODIFIED GREAT SAPHENOUS VEIN FOR HEPATIC VEIN RECONSTRUCTION IN RIGHT-LOBE LIVING DONOR LIVER TRANSPLANTATION
2071	Maxat Doskhanov	PORTAL FLOW MODULATION IN LIVING DONOR LIVER TRANSPLANTATION
2072	Qin Luo	Role of TRIM37/IKKγ axis in hepatic ischemia/reperfusion injury
2073	Qin Luo	FAM49B inhibits TRAF6 ubiquitination and alleviates liver ischemia reperfusion injury
2074	Chia-Yen Dai	Prediction of Non-Alcoholic Fatty Liver Disease by Machine Learning Algorithms
2075	Omar Elkoumi	Efficacy and safety of transarterial chemoembolization plus dual immune and anti-angiogenic blockers for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
2076	Ning Yao	Xiaozhi Huaxian Formula ameliorates type 2 diabetes mellitus-associated metabolic dysfunction-associated steatohepatitis through modulating hepatic interleukin-23/interleukin-17 Axis
2077	Ning Yao	Xiaozhi Huaxian Formula ameliorates type 2 diabetes mellitus-associated metabolic dysfunction-associated steatohepatitis through modulating hepatic interleukin-23/interleukin-17 Axis
2078	Pei-Chien Tsai	Highly Discriminative Risk Stratification for Long-Term Liver-Related Mortality in MASLD Patients
2079	Weihua Cao	Clinical characteristics of patients with primary biliary cholangitis across various disease stages
2080	Muhammad Firdaus Md Salleh	Comparing Care Settings for Sofosbuvir/ Ravidasvir Delivery in Hepatitis C: Nested Cohort Findings from the EASE Trial
2082	Muhammad Firdaus Md Salleh	Time to Viral Load Suppression with 8- versus 12-Week Ravidasvir/Sofosbuvir Regimens among Chronic Hepatitis C Patients in Malaysia
2084	Shu-Hua WANG	Workflow Optimization to Reduce Chemotherapy Drug Waiting Time in Inpatient Settings
2085	Xuhui Ma	Inhibition of Aurora B Induces Senescence and Potentiates Immunotherapy in Hepatocellular Carcinoma
2088	Angelica Mariano	The Effect of Semaglutide on Liver Histology in Metabolic Dysfunction Associated Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2089	Mohammed Tozammel Haque Haque	Secondary Biliary Cirrhosis Following Iatrogenic Bile Duct Injury
2090	Jiaran Sun	Integration of Microbial Signatures into Machine Learning Models Significantly Improves Prediction of Adverse Outcomes in Patients with Hepatitis B-Related Cirrhotic Ascites
2091	mainuddin ahmed	Treatment outcome of interferon based therapy versus sofosbuvir ribavirin therapy in chronic hepatitis C genotype 3 and compensated liver cirrhosis
2093	Zhao yiru Zhao	Effects of Extracellular Vesicles Secreted by Gut Microbiota on the Function of Peripheral CD8+ T Cells and Regulatory T Cells in Patients with Hepatocellular Carcinoma
2095	Xiaohong Gao	Preliminary Evaluation of Real-World Efficacy and Safety of Tenofovir Prafulvate Tablets in the Treatment of 16 Patients with Chronic HBV Infection
2096	Xiaohong Gao	Case Report of Decreased Cholinesterase Levels During Treatment with Prifosfamide Mesylate in a Patient with Chronic HBV Infection
2097	Stine Koball	Improving Elimination in Albumin-Dialysis Liver Support: Different Responses of Water-Soluble and Albumin-Bound Toxins
2098	Xiaohong Gao	An Observational Study on the Early Intervention Treatment of Fuzheng Huayu Capsule Combined with Antiviral Drugs in High-Risk Populations of HBV-Related Hepatocellular Carcinoma
2099	Xiao Hong Gao	Clinical Analysis of Early Renal Injury in HBV-Infected Patients Treated with Nucleos(t)ide Analogues
2101	Weihua Cao	A Non-invasive Diagnostic Prediction Model for AMA-Negative Patients with Primary Biliary Cholangitis
2103	Diğdem Kuru Öz	Association of MR elastography parameters with prognostic indices, neutrophil-to-lymphocyte ratio, hepatocyte function, and cholestasis parameters in chronic liver disease
2106	Terry Cheuk-Fung Yip	Disease burden of chronic hepatitis B among pregnant women increased dramatically with age – a territory-wide study

Paper No	Presenter	Title
2108	Mohammad Forhad Abedin Abedin	Post–Liver Transplant Outcomes and Donor Safety in Bangladesh: A Nationwide Questionnaire-Based Observational Study
2109	Masato Nakai	Soluble CD14 Predicts Prognosis, Diuretic Response, and Acute Kidney Injury in Decompensated Cirrhosis with Refractory Water Retention
2111	Sinan Mermer	Prevalence of Liver Enzyme Abnormalities in PCR-Confirmed Respiratory Viral Infections: A 321-Patient Cohort
2112	Bingqing Yang	Core genes with opposite expression changes and their inflammation-related regulatory network during the progression and regression of NASH liver fibrosis
2114	Qian Wang	Targeted Activation of Lipophagy Attenuates MASH Progression in a Murine Model
2115	Frances Melissa Cielo	Determinants of severe liver fibrosis in patients with MASLD: a five-year retrospective cross-sectional study
2116	Frances Melissa Cielo	Acute liver failure after transarterial embolization of hemorrhaging hepatocellular adenoma
2118	Hassan Mahmood	Hepatitis B and C Prevalence Among Transgender Individuals and Men Who Have Sex with Men in Pakistan
2119	Huma Qureshi	Introducing Hepatitis B Birth Dose Vaccination Within 24 Hours of Birth: A Pilot Project in Pakistan
2120	Chun-Ying Wu	GLP-1 receptor agonists associated with reduced risk of digestive cancers in patients with diabetes: global real-world evidence
2122	Shinya Endo	Effect of a Porous Glass-Membrane Emulsification Method on Radiological Response in Epirubicin–Lipiodol cTACE for HCC
2123	Xiao Lin	Efficacy and safety of glucocorticoids in multi-etiology liver injury: a single-center real-world retrospective cohort study
2126	Eman Rewisha	Pemphigus vulgaris in immunotherapy of hepatocellular carcinoma and response to treatment
2127	Ying Lu	Association of copper exposure with fatty liver progression and mediation by perturbation of metabolic pathways
2128	Jinjin Liu Liu	Triglycerides and high-density lipoprotein cholesterol are primary lipid determinants of steatosis severity in metabolic dysfunction-associated fatty liver disease
2129	Hong-Li Liu	Bile Duct Reduction Without Ductular Reaction: A Key Pathological Feature of Alagille Syndrome
2131	PRONOY PEREIRA	PROGNOSTIC VALUE OF SERUM AMMONIA FOR SHORT-TERM MORTALITY IN CIRRHOSIS: A SYSTEMATIC REVIEW
2133	Huma Qureshi	Hepatitis (B, C & D) and HIV Seroprevalence Survey in Sindh Province, Pakistan
2135	Hassan Mahmood	Assessing HCV Re-infection Rates and Linkage to Care among Transgenders and MSM in Pakistan: A Follow-up Study
2136	Hassan Mahmood	Implementing a Micro-Elimination Program for Hepatitis C and Hepatitis B Diagnosis and Referral in Khairpur District, Sindh Province, Pakistan: A Pilot Project for National HCV Elimination Initiative
2138	Huma Qureshi	Evaluation of the Elecsys HCV Duo Assay for Screening and Testing of Hepatitis C Virus in Pakistan
2139	Yunlong Yao	Multi-Omics Biomarkers for Early Detection of Metabolic Dysfunction–Associated Fatty Liver Disease
2140	Huma Qureshi	A cost-effective analysis of transportation of blood for HCVRNA using the plasma preparation tube vs the plasma separation card
2141	YunLong Yao	Environmental Toxicity–Related Metabolic Signatures and Disease Severity in MAFLD
2142	YunLong Yao	Artificial Intelligence–Assisted Ultrasound Imaging for Non-Invasive Assessment of Liver Fibrosis
2144	Yosra Khalifa	Beyond complete response of advanced hepatocellular carcinoma to immunotherapy, what can we do?
2146	YunLong Yao	Inhibition of TGF-β Signaling Attenuates Liver Fibrogenesis in an Experimental Cirrhosis Model
2147	YunLong Yao	Single-Cell Transcriptomics Reveals Distinct Hepatic Stellate Cell Subpopulations Driving Liver Fibrogenesis
2149	Bushra Shahid Shahid Hussain	Hepatitis E Vaccination in Women of Childbearing Age: outcome and Implementation Challenges.
2151	Ran Zhao	HBV infection accelerates hepatocyte senescence and induces T cell exhaustion via SASP secretion pathway
2153	NATHANIEL CAMANGON	When the Heart Fails, the Liver Breaks: Congestive Cholestasis Presenting as ACLF, A Case Report and Literature Review
2154	Rakesh Sugathan Sugathan	“Saroglitazar in MASLD: Translating Clinical Trials into Practice Through Liver Metrics
2155	Xi Zhang	Gut Microbiota Dysbiosis Correlates with Disease Severity in Autoimmune Hepatitis
2156	Xi Zhang	Combination Immune Checkpoint Inhibition and Antiangiogenic Therapy Improves Survival in Advanced Hepatocellular Carcinoma
2157	Ghulam Mohiuddin	A Rare etiology of Liver mass in a patient of chronic Hepatitis C
2158	Rakesh M Nair	“Evaluating the Early Biochemical Impact of Saroglitazar on Liver Function Tests in MASLD Patients
2159	Ghulam Mohiuddin	A rare lymphoproliferative disorder in teenagers with spontaneous resolution on PET scan.
2160	Demver Gomez	Finite versus indefinite nucleos(t)ide analogue therapy in HBeAg‑negative chronic hepatitis B: Meta‑analysis of Randomized Trials.
2162	Ghulam Mohiuddin	A rare cause of Gastric malignancy with liver metastasis in a young Patient.
2163	Ghulam Mohiuddin	A rare etiology of Liver mass in a patient of chronic Hepatitis C
2164	Xi Zhang	AAV-Mediated ATP7B Gene Therapy Corrects Copper Metabolism in a Wilson’s Disease Mouse Model
2165	Ghulam Mohiuddin	A rare lymphoproliferative disorder in teenagers with spontaneous resolution on PET scan.

Paper No	Presenter	Title
2166	YunLong Yao	Whole-Genome Sequencing Identifies Novel Genetic Mutations in Unexplained Pediatric Cholestatic Liver Disease
2169	Ghulam Mohiuddin	Multiple Cutaneous and Gastrointestinal Hemangiomas Presenting with Iron Deficiency Anemia: A Rare Case Report of Blue Rubber Bleb Nevus Syndrome.
2170	Abdulwahab Alqahtani	PROBABLE ASHWAGANDHA-INDUCED HEPATITIS IN A HEALTHY YOUNG ADULT: A CASE REPORT
2171	Federico Peralta	HBV RNA as a Predictor of Hepatocellular Carcinoma in Antiviral-suppressed Chronic Hepatitis B: A Systematic Review and Meta-analysis
2173	Alaa M. Mostafa	Dietary Recommendations for Patients with Chronic Liver Diseases: The Need for Increased Awareness Among Non-Hepatologist Physicians
2174	Alaa M. Mostafa	MAFLD aggravates Colorectal Cancer Progression: A quantitative MRI-PDFF-based study
2175	Alaa M. Mostafa	High Prevalence of Unrecognized Advanced Fibrosis in Patients with MAFLD
2176	Alaa M. Mostafa	Metabolic predictors of Liver fibrosis across MAFLD phenotypes: A cross-sectional study using Transient Elastography
2177	Yasser Fouad	MAFLD-CKM: Modified score better predicts long-term all-cause mortality
2178	Md Yasir Arafat	Predictors and gaps in hepatocellular carcinoma staging and management: A multicenter, prospective study in Bangladesh
2179	Du Leilei	Correlation analysis of HBVRNA and hepatitis B virological and biochemical indicators in treated chronic HBV-infected patients
2180	Du Leilei	The value of serum HBV RNA in the diagnosis, treatment and prognosis of chronic hepatitis B
2181	雷雷 杜	Analysis of the clinical efficacy of sequential combined Peg-IFN treatment after NAs treatment in CHB patients
2182	Xin Ai	Comparison of multiple drugs for metabolic dysfunction-associated fatty liver disease: A systematic review and network meta-analysis
2183	Shiyu Wang	Predictors of HBsAg Clearance and Development of a Nomogram in Chronic Hepatitis B Patients with Low-Level Viremia Treated with Pegylated Interferon α-2b
2184	Yingying Zhao	Related factors of fever after endoscopic treatment of variceal bleeding in patients with liver Cirrhosis complicated with esophageal variceal bleeding: A retrospective study
2186	Xiaobo Lu	Demographic Characteristics and Treatment Status of Primary Biliary Cholangitis: A Single-Center Study from Xinjiang, China.
2187	Dave Christian Ong	Budd-Chiari Syndrome Secondary to Combined Protein C, Protein S, and Antithrombin III Deficiencies in a Young Filipino Woman: A Rare Case Report
2190	Hui Huang	A novel intratumoral microbial risk score predicts survival and characterizes the immunosuppressive microenvironment in hepatocellular carcinoma
2191	Mohamed AbdAllah	Evolution of hepatocellular carcinoma staging within Egypt's national surveillance system: a success story (2019–2024)
2193	Xinghuan Fu	Serum sIL-2R Predicts Significant Histological Disease in Indeterminate Phase Chronic Hepatitis B
2194	Youngnam Kim	A case of hepatocelluar carcinoma developed after antiviral treatment cessation due to HBsAg seroclerance.
2196	Shifan Liu	Early Risk Prediction of Hepatocellular Carcinoma in Cirrhosis Patients Based on Non-Contrast CT
2197	Xin Yue	A survey of the current status of research on the diagnosis and treatment of hepatitis C virus antibody-positive pregnant women
2198	LEAMSI GAY ARPON	"When Natural Becomes Toxic: Herbal Medicine–Induced Acute Liver Failure Treated With Double Plasma Molecular Adsorption System"
2199	Shuo Huang	Bridging numerical scores and lived experience in acute and chronic liver failure
2200	LEAMSI GAY ARPON	Acute Liver and Gastric Injury Complicated by Acute Kidney Injury Following Massive Ferrous Sulfate Overdose: A Case Report
2202	Shuo Huang	Bridging numerical scores and lived experience in acute and chronic liver failure
2203	Shuo Huang	Why definitions of acute on chronic liver failure matter for trials and everyday decisions
2204	Shuo Huang	Fragmented collaboration between liver and addiction services in alcohol related liver disease
2205	Shuo Huang	Misaligned clinical and patient defined recovery in alcohol related liver disease
2206	Shuo Huang	Silent degradation of artificial intelligence tools for liver disease in routine care
2207	Shuo Huang	Making artificial intelligence in hepatology more holistic and aligned with clinical reasoning
2208	Shuo Huang	How endocrine information is missing from contemporary chronic liver disease research
2209	Shuo Huang	Overlapping metabolic reproductive and hepatic disturbance in women with fatty liver disease
2210	Anam Shakeel	"Demographic Characteristics of MAFLD with Emphasis on Young-Onset Disease in Pakistan
2211	Md.Musab Khalil	Frequency of metabolic dysfunction associated steatotic liver disease (MASLD) amongst patients with inflammatory bowel disease (IBD)
2212	Eman Rewisha	Regorafenib as a second line therapy for Egyptian patients with an advanced stage HCC: real life data from a single center
2213	Jina Park	Pain Management Gaps in Hepatocellular Carcinoma: A Cross-Sectional Survey Study of Patient Perceptions, Misconceptions, and Unmet Needs
2216	Akira Uchiyama	Gut-derived microbial nucleic acids modulate hepatic innate immune responses in steatotic liver disease
2217	Lisha Shi	The Impact of Prophylactic Antibiotics on the Prognosis of Patients with Cirrhosis and Upper Gastrointestinal Bleeding
2219	Guanyue Su	Higher matrix stiffness accelerates liver fibrosis by modulating fatty acid oxidation via PPARα/CPT1A signaling axis in hepatic stellate cells

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2220	Atsushi Hosui	Prospective Study on Prognostic Improvement and Suppression of Hepatocellular Carcinoma Development after Zinc Supplementation in Patients with Liver Cirrhosis Background and Aim
2221	Tianhui Zhou	FABP4 as a Prognostic Biomarker and Its Clinical Relevance in Drug-Induced Cholestasis
2222	Weihua Cao	The correlation between autoantibody spectrum and clinical pathological phenotype of Primary Biliary Cholangitis Patients
2223	Xiaoli Ma	Hepatic IGFBP3 Attenuates Osteoblastic Differentiation in Cirrhotic Liver‑Bone Axis via NF‑κB Signaling
2224	Darayus Percy Gazder	Hepatitis D-related liver disease as a major indication for liver transplantation: experience from a new liver transplant program in pakistan
2227	Emerald Gersava	Unilateral Sialadenosis as Initial Presentation of Alcoholic Hepatitis: A Case Report
2228	Javaria Younas Muhammad Younas	HBsAg Levels as Predictors of Fibrosis in Chronic Hepatitis B: A Systematic Review and Meta-analysis
2230	Javaria Younas Muhammad Younas	HBsAg Levels as Predictors of Fibrosis in Chronic Hepatitis B: A Systematic Review and Meta-analysis
2231	Soe Thiha Maung	Hepatocellular Carcinoma Surveillance among Chronic Hepatitis C patients after successful SVR: Systematic Review and Meta-analysis of Economic Evaluation Studies
2232	Javaria Younas Muhammad Younas	Diagnostic Accuracy of FIB-4 Score for Detecting Advanced Fibrosis in NAFLD: A Systematic Review and Meta-analysis
2233	Shahira El-Etreby	Real-World Two-Year Outcomes of Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: Single-Center Experience
2234	Shahira El-Etreby	Preliminary results of STRIDE regimen in Egyptian HCC patients: A Single-Center Real-World Experience
2235	Israr Ullah Abdul Qadeem	Association Between HbA1c Levels and Risk of Liver-Related Events in NAFLD Patients: A Systematic Review and Meta-analysis
2236	Jiajia Zhou	Cimicifugae Rhizoma Suppresses Hepatoblastoma Proliferation by Downregulating G6PD Expression
2237	Chunyan Ruan	RSRC1 Promotes Hepatocellular Carcinoma Progression by Mediating Homologous Recombination Repair and Regulates Sensitivity to PARP Inhibitors
2238	Wei Hou	UNCOVERING THE ONCOGENIC ROLE OF PKMYT1 IN HEPATOCELLULAR CARCINOMA THROUGH INTEGRATED BIOINFORMATICS
2239	Xiucheng Pan	The ratio of GGT to PLT indices is a predictive factor for the progression of liver fibrosis in NA-treated chronic hepatitis B patients with advanced fibrosis plus PEG-IFN α-2a therapy:
2242	Jie Liu	Dynamic Survival Prediction and Treatment Adjustment System for Advanced Biliary Tract Cancer
2243	Hongliang Liu	Qutan huoxue decoction alleviates MASH-induced fibrosis by regulating LC3-mediated macrophage mitophagy
2246	Jinyi Wu	Sulforaphane Inhibits N-Nitrosodimethylamine induced Hepatocellular Carcinoma Stem Cell Properties via ZNF652/Sonic Hedgehog axis
2247	Delgermurun Batkhurel	ASSESSMENT OF HEPATOCELLULAR CARCINOMA RISK USING COMBINED SERUM FERRITIN, AFP, AND PIVKA-II BIOMARKERS
2248	Xiang Huang	ERα-FGF13-PROX1 cascade regulates fatty acid β-oxidation to mediate sexual dimorphism in MAFLD
2249	Hyun Phil Shin	Maternal High-Fat Diet Induces Lifelong Epigenetic Priming and Trained Immunity Driving Offspring Susceptibility to MASLD
2250	Wenlong Miao	Piezo1 mediates matrix stiffness-induced hepatic stellate cell activation by inhibiting mitophagy in liver fibrosis
2251	Mery Friyanti Pandiangan	Multisystem Involvement Of Salmonella Infection: Liver Abscess With Secondary Pleural Effusion In Diabetes Mellitus
2253	Jian Wang	Discrepancies in Treatment Eligibility Across Different International Guidelines for Chronic Hepatitis B
2257	Shuxian Zang	Construction and Validation of a 90-Day Prognostic Prediction Model for Patients with Acute-on-Chronic Liver Failure After Artificial Liver Support Therapy
2258	春润 李	DNA Methylation Profiles Predict MASLD Progression
2259	Lijuan Chen	Managing Portal Hypertension Complications in Hepatic Arterioportal Fistula: The Role of Transcatheter Arterial Embolization
2260	Hafsa Abdul waheed jadgal	Comparative Analysis of MAFLD in Diabetic vs. Non-Diabetic Patients: Metabolic and Fibrotic Profiles
2261	Wei Hou	UNVEILING THE ONCOGENIC AND PROGNOSTIC ROLE OF KRT17 IN HEPATOCELLULAR CARCINOMA
2262	春润 李	Circadian Clock Disruption Drives MAFLD Through Bile Acid Dysregulation
2263	春润 李	Social Jetlag Disrupts Pituitary Hormone Rhythm to Drive MASLD
2264	Jian Wang	Impact of Updated International Guidelines on Treatment Eligibility for Chronic Hepatitis B
2265	Na Fu	Construction and Validation of a 90-Day Prognostic Prediction Model for Patients with Acute-on-Chronic Liver Failure After Artificial Liver Support Therapy
2266	春润 李	Yang-Deficiency Constitution and Altered Bile Acid Metabolism in MAFLD
2267	春润 李	Qi-Stagnation Constitution Predisposes to Hepatic Microcirculatory Dysfunction in MAFLD
2269	Odessa Pekas	Hepatoduodenal fistula as a complication of Hepatobiliary tuberculosis: A case report
2270	Yuanye Ji	TweakR promotes hepatic fibrosis via NF-κB signaling in metabolic dysfunction-associated fatty liver disease and intervention by obacunone
2271	春润 李	Machine Learning Predicts MASLD Fibrosis Risk via TCM Constitution Clusters
2272	Hongbin Zhu	Interventional Embolization of Spontaneous Portosystemic Shunts Improves Survival in Decompensated Cirrhosis: A Retrospective Matched Analysis

Paper No	Presenter	Title
2273	春润 李	Yin-Deficiency Constitution Predisposes to HCC via Gut-Immune Dysregulation
2275	春润 李	Dampness-Heat Constitution Impairs Adipose Browning in MASLD
2277	春润 李	Balanced Constitution Maintains HPA Axis and Hepatic Gluconeogenesis
2278	春润 李	Spatiotemporal Transcriptomics Decodes Constitution-Specific Liver Zonation
2279	春润 李	Constitution-Specific Gut Flora Directs Liver Epigenome in MAFLD
2280	春润 李	Atopic Constitution Primes Hepatic ILC2-Macrophage Axis in MASLD
2281	春润 李	Reversing Qi-Deficiency Slows Hepatocyte Senescence via AI
2283	春润 李	Phlegm-Dampness Constitution Disturbs Hepatic Circadian Rhythms in MASLD
2284	春润 李	Stomach-Heat Constitution Impairs Postprandial Hepatic Metabolic Flexibility
2285	春润 李	Blood-Stasis EVs Reprogram Hepatic Stellate Cells via YAP
2286	春润 李	Atopic Constitution Primes Liver Metastasis via Gut-EV Immunomodulation
2287	Naila Naz	Bioactive Folate Supplementation Mitigates Valproic Acid–Induced Liver Injury and Steatosis in a Rat Model
2288	Xiaohong Gao	Adverse reaction report of Peg - IFN - α - 2b in 14 cases of compensated hepatitis B liver cirrhosis patients treated with NAs
2289	Jian-Hong Zhong	Tumor burden score combined with alpha-fetoprotein stratification: Evaluating efficacy of triple conversion therapy in unresectable hepatocellular carcinoma – A multicenter retrospective study
2293	Ilknur Cakmak	Rhabdomyolysis-triggered acute-on-chronic liver failure in alcohol-related cirrhosis: a rapidly fatal multiorgan failure case
2295	Serhat Akpınar	Acute methyl ethyl ketone peroxide poisoning presenting with polycythemia
2298	Shuntaro Obi	Divergent Oncologic and Survival Implications of Stiffness Regression After SVR: A Decade-Long Longitudinal FibroScan Study in Advanced Fibrosis
2299	Selma Tosun	Shifting hepatitis A virus seroprevalence among healthcare workers and the general population
2301	Soichiro Hase	Gastric Variceal Rupture due to Sinusoidal Obstruction Syndrome after Oxaliplatin Chemotherapy
2303	Yanwei Zhong	Predictive Value of Peripheral Blood T Cell Counts for HBsAg Clearance in Pediatric Patients with Chronic Hepatitis B Receiving Antiviral Therapy
2304	Dr Darayus Percy Gazder	Hepatocellular carcinoma detection using pre-transplant triphasic computed tomography and correlation with explant pathology
2305	Yanwei Zhong	Transcriptomic Characteristics of Peripheral Blood T Cells in Pediatric Chronic Hepatitis B with Different Antiviral Therapy Outcomes
2307	DESIREE JANE LACUIN	The Thirteen-Year Shadow: Delayed Biliary Cirrhosis Following Gallbladder Tuberculosis in a Young Filipino Female
2308	Yanwei Zhong	Application of Anti-HBc in Clinical diagnosis for Pediatric Hepatitis B
2312	Airu Liu	A Rare Case Report of Primary Hepatic Lymphoma Complicated by Hemophagocytic Lymphohistiocytosis
2313	Yan Wang	The role of hepatic CD36 in metabolic dysfunction-associated steatotic liver disease
2315	Cathleen Kenya	Epidemiological and clinical characteristics of hepatocellular carcinoma: a 10 year registry from tertiary private cancer centre hospital
2316	Haiyu Wang	Precision ablation with nanosecond pulsed electric field (nsPEF) in early hepatocellular carcinoma: a phase I trial integrating multi-omics analysis
2317	Esraa Kamal	The identification of a novel compound suppressing the early stages of Hepatitis B Virus (HBV) infection
2319	Shaodong Li	The Cancer Cell-Hepatocyte Interface in Colorectal Cancer Liver Metastasis: Mechanisms and Clinical Translation
2321	Farhana Kayani	A novel prognostic model to predict mortality in patients with drug induced liver injury in intensive care unit, a study from Pakistan
2322	SAUL SUAYBAGUIO	Gut Microbiota Modulation on Non-Alcoholic Fatty Liver Disease Progression: A Systematic Review and Meta-Analysis from Human Trials
2323	SAUL SUAYBAGUIO	RNAi Therapies for HBsAg Reduction in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Early-Phase Trials
2324	SAUL SUAYBAGUIO	Association of Serum Amylase and Lipase with Clinical Outcomes of Leptospirosis Patients at a Philippine Tertiary Government Hospital: A Retrospective Cohort Study
2325	Ning Yao	Rabdosia Rubescens Inhibits Toll-Like Receptor 4-Dependent Helper T Lymphocytes Infiltration in the Liver of Type 2 Diabetes-Associated Metabolic Dysfunction-Associated Steatohepatitis Mice
2327	Farhana Kayani	Impact of Metabolic Dysfunction–Associated Fatty Liver Disease on Severity and Recovery of Drug-Induced Liver Injury: Experience from a Pakistani Cohort
2330	Jialu Yang	Dietary omega-3 and omega-6 Polyunsaturated Fatty Acid Intake and Mortality Among Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study
2331	Qin Xiao	Prognosis of ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single-center cohort study from China
2332	Aparna Morgan	Hepatocellular carcinoma without cirrhosis in Australasia: an under-represented but high-risk population
2333	Manal Cherkaoui Malki	Evaluation of Liver Fibrosis Before and After Treatment of Chronic Hepatitis B

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2334	Manal Cherkaoui Malki	US-guided liver biopsy: Fine-needle aspiration versus semi-automatic cutting needle
2337	ian yang Liew	Diagnostic challenges at the interface of drug-induced autoimmune hepatitis and classical autoimmune hepatitis : a case report
2338	Amarsanaa Jazag	Association between Glycemic Control (HbA1c) and Liver Transaminase Levels (ALT and AST) in Mongolian patients
2339	Shanshuo Liu	The metagenomics-derived gut mycobiome biomarker for non-invasive diagnosis of early hepatocellular carcinoma
2341	Amarsanaa Jazag	Correlation Between tumor markers (AFP, CA19-9, CEA)
2342	Adinda Amalia	Performance of Non-invasive Baveno Seven Criteria for Predicting Clinically Significant Portal Hypertension in Burned-out Metabolic Dysfunction-associated Fatty Liver Disease
2343	Jalal Khan	Gut Microbiome Dysbiosis in Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-Analysis , Pakistan
2344	Kübra Bağır	Is Pneumococcal Vaccination Safe in Patients with Liver Cirrhosis?
2345	Farhana Kayani	Gut Microbiota Alterations in Patients with Chronic Hepatitis B and Metabolic Associated Fatty Liver Disease: Implications for Fibrosis Progression
2346	Amarsanaa Jazag	Correlation Between Liver Biomarkers and Hemoglobin Levels in Mongolian Patients
2348	Dr. Shoumeta Damle	Observational study comparing Hepatocellular carcinoma patients on HCC surveillance with those not on surveillance at diagnosis.
2352	Ron-Daniel Gison	The Economic Burden of Cirrhosis: Financial Classification and Disease Severity as Key Predictors of Direct Hospital Costs in the Philippines, a Retrospective Analysis
2354	Amarsanaa Jazag	COMPARATIVE STUDY OF THE ETIOLOGY OF LIVER CANCER AND THE MANIFESTATION OF HEPATIC ENCEPHALOPATHY
2355	Charlene Cheong	A Machine Learning-Based Screening Tool for Population-Level Screening of MASLD to identify outlier patients current tools miss
2356	Xuemei Wang	Mechanism research of α-Amyrin targeting Sirt1/PGC-1α/PPARα axis to regulate fatty acid metabolism reprogramming against liver fibrosis
2357	Aditya Soni	Pediatric Seronegative Autoimmune Hepatitis has a comparable clinical and laboratory profile to Seropositive Disease
2358	Aziza Khikmatullaeva	Serum HBV RNA as a Marker of Occult HBV Infection in Patients with Hepatocellular Carcinoma
2362	Aditya Soni	Gallstone Disease in Pediatric Wilson Disease: Prevalence, Risk Factors and Outcome
2363	HuiChuan Sun	An Innovative Digital Oncology Platform for Enhanced Precision Management of Hepatocellular Carcinoma in China
2365	Darryl John Pasamba	Cholangioscopy-Guided Diagnosis of Acquired Biliary Web in a Pediatric Patient: A Case Report
2366	Do Seon Song	Sex Disparities in Hepatocellular Carcinoma in a Korean Nationwide Cohort
2367	Jian-Hong Zhong	Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: an update analysis of a phase 2 trial
2370	Can Zhang	Comparison of surgical resection, percutaneous ablation, and transarterial chemoembolization for hepatocellular carcinoma in patients with recompensated cirrhosis: a multicenter, retrospective, cohort study
2371	Archana Rastogi	Prevalence and Significance of Portal Tract Histological Changes in Metabolic Dysfunction–Associated Steatohepatitis
2372	Sylwan Rahardja	Refractory Cytomegalovirus Colitis Complicating Ulcerative Colitis After Liver Transplantation: The Role of Serial Intestinal Ultrasound
2373	Rihwa Om	One-step in-hospital HCV screening using a qualitative dual-detection immunoassay for HCV core antigen and antibodies (Elecsys HCV Duo): initial implementation and performance
2376	Abhishak GUPTA	PNPLA3 I148M and E434K Variants drive Lipid Dysregulation in Pre-diabetes and Diabetics
2379	Yunzhi Zhang	Exploring The Inflammatory-Cancer Transformation From MASLD To Hepatocellular Carcinoma Using Multi-Omics And Machine Learning
2380	LEAMSI GAY ARPON	The Unexpected Twist: Distal Esophageal Obstruction After Rubber Band Ligation in a 51-Year-Old Woman with Decompensated Liver Cirrhosis
2382	Zhen Tian	A Novel VExUS-Based Model Integrating Renal Venous Congestion and Mesenteric Hemodynamics for Noninvasive Risk Stratification of High-Risk Esophageal Varices in Cirrhosis
2383	Zhigang Ren	Multikingdom and functional gut microbiota markers for cholangiocarcinoma
2384	Yanwei Zhong	Key T Cell Characteristics Associated with Suboptimal Treatment Responses in Pediatric Chronic Hepatitis B
2387	Zhen Tian	A Comprehensive Ultrasound Model Integrating Gastrointestinal and Hemodynamic Parameters for Non-Invasive Risk Stratification of Esophageal Varices
2388	Yanwei Zhong	Serum ATX Predicts Posthepatectomy Recurrence in HBV-Related HCC
2391	Mehmet Yıldız	Apilarnil Alleviates Potassium Dichromate-Induced Hepatotoxicity in Rats by Modulating the Ferroptosis Pathway (GPx4/TFRC)
2392	Seok Hyun Kim	Plug Assisted Retrograded Transvenous Obliteration for Gastric Varices Treatment
2393	Zhen Tian	Lipopolysaccharide Inhibits Autophagy and Promotes Inflammatory Responses via p38 MAPK-Induced Proteasomal Degradation of Atg13 in Hepatic Stellate Cells
2396	Ariunzaya Munkhchuluun	Comparison of Bevacizumab Treatment Outcomes by Hepatitis Virus Infection, Gender, and Age Group

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2397	Xi Zhang	Immune Profiling Reveals Distinct Cytokine Signatures in Autoimmune Hepatitis Flares
2399	Jing Chen	Trends in Cholangiocarcinoma Mortality and Incidence in Asia, 2000–2023: Insights from Joinpoint Analysis
2400	YunLong Yao	Rituximab Achieves High Remission Rates in Steroid-Refractory Autoimmune Hepatitis: A Controlled Pilot Trial
2401	Xue Bai	A Model Incorporating Serum N-Terminal Propeptide of Type III Collagen and Platelet Count Predicts Advanced Fibrosis in Chronic Hepatitis B
2402	Oyunselenge Baatarmunkh	Association Between Three-Month Average Blood Glucose Levels and Hepatic Steatosis and Liver Fibrosis
2403	Qiran Zhang	Optimizing Community-Based Hepatitis C Screening Strategies: Package of Point-of-care Testing, Reflex Testing and Big Data-Based Risk Concentration
2405	YunLong Yao	Predictors of Relapse After Immunosuppressive Therapy Withdrawal in Autoimmune Hepatitis
2407	Ariunzaya Munkhchuluun	Comparison of Bevacizumab Treatment Outcomes (Measured by Number of Courses) with Biopsy Characteristics
2408	Tserendulam Dorjsuren	ASSOCIATION BETWEEN SERUM IRON LEVELS AND HEPATIC STEATOSIS
2409	YunLong Yao	Deep Learning-Assisted Ultrasound Improves Early Hepatocellular Carcinoma Detection in Cirrhosis
2411	YunLong Yao	A Machine Learning Model Predicts Hepatic Decompensation Risk in Compensated Cirrhosis
2412	Ping Lv	Influence of clinical stages of decompensated cirrhosis on optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS
2413	Xi Zhang	Breath Volatile Organic Compounds and Machine Learning Enable Non-Invasive Detection of Early MAFLD
2414	delgermurun batkhurel	COMBINED ASSESSMENT OF FERRITIN, AFP, AND PIVKA-II IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA
2415	Xi Zhang	Fenofibrate Add-On Therapy Improves Biochemical Response in Primary Biliary Cholangitis Patients with Incomplete UDCA Response
2416	Xi Zhang	Oral Vancomycin Therapy in Primary Sclerosing Cholangitis: A Pilot Study Demonstrates Biochemical Improvement
2417	Oğuzhan Acet	Clinical Course and Short-Term Outcomes of Acute Hepatitis B in a Tertiary Liver Transplant Center
2419	Adinda Amalia	Generalized Pustular Psoriasis Complicated by Metabolic Dysfunction-Associated Fatty Liver Disease and Immunosuppressive Therapy–Associated Transaminitis: Highlighting the Skin–Liver Inflammatory Axis
2420	YunLong Yao	Autoimmune Hepatitis–Primary Biliary Cholangitis Overlap Syndrome: Clinical Characteristics and Comparative Outcomes
2421	ADRIAN BUGAYONG	When Etiologies Intersect: Concomitant Hepatitis B Reactivation, Hepatic Tuberculosis, and Choledocholithiases in a Filipino Male Presenting with Jaundice
2423	Jing Zhou	Snat1-Mediated Glutamine Reprogramming in Macrophages Accelerates MAFLD-Associated Colorectal Cancer Liver Metastasis
2424	Stacey Scherbakovsky	Sustained virologic response 4 testing as a measure of hepatitis C virus cure in re-treated patients following direct-acting antiviral failure: A sustained virologic response 4/12 concordance evaluation from POLARIS trials
2425	Yrah Damiene Fernandez	POST ERCP DUODENAL HEMATOMA AS A CAUSE OF GASTRIC OBSTRUCTION
2428	Yu-Ting Xiong	Glucocorticoid Therapy Modulates HMGB-1 and K18 Levels in Chronic Drug-Induced Liver Injury
2429	Hanife Nur Karakoc parlayan	Effects of Switching from Tenofovir Alafenamide Fumarate to Tenofovir Disoproxil Fumarate or Entecavir on Lipid Parameters and Atherosclerotic Cardiovascular Disease Risk
2430	Yi-Fan Guo	HBsAg Quantification-Based Models for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B: The HCC-HBsAg Score
2431	Yu-Ting Xiong	Metabolomics Reveals Metabolic Reprogramming and Novel Biomarkers in Glucocorticoid-Treated Chronic DILI
2434	Yancai ZHOU	Clinical HCC Predictors in HBV-related Cirrhosis: A Real-World Study
2435	Shujuan Gong	Safety and Efficacy Analysis of Argon-Helium Cryoablation Combined with Targeted Drugs and Programmed Death Receptor 1 Monoclonal Antibody in Elderly Patients with Unresectable Hepatocellular Carcinoma
2436	ÖZLEM BAYRAKTAR SARAL	Causative Pathogens of Intra-abdominal Abscesses Following Whipple Procedure and Comparison with Expected Abdominal Flora
2437	Asma Yaseen	Advancing Pediatric Care in Gastroenterology:Endoscopic Ultrasound in Pediatrics at a Referral Endoscopy Center in Pakistan
2442	Selma Tosun	Comparison of gestational age and birth weights of infants born to HBsAg-positive and HBsAg-negative pregnant women
2444	Aayan Shaheer Sheikh	Bioinformatics Mapping of Ferroptosis Pathways in NAFLD Progression
2445	Aayan Shaheer Sheikh	Ferroptosis-Linked Cell-Cycle Hub Genes Reveal New Therapeutic Angels in Sepsis
2446	Aayan Shaheer Sheikh	Shared and stage-Specific ferroptosis related biomarkers Across NAFL and NASH: An RNA-seq Analysis
2447	Kadir Gisi	Hepatitis B reactivation secondary to rituximab treatment
2448	Aayan Shaheer Sheikh	DNA microarray-based identification of ferroptosis-related biomarkers in alcoholic hepatitis
2449	Safaa M Abdelhalim	Real-World Barriers to Post-SVR Monitoring in HCV: Insights from a Physician Survey
2451	Archana Rastogi	Late T-cell mediated Rejection (TCMR) in liver allograft biopsies: Impact of heterogeneity on the progression to chronic TCMR

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2452	Nitesh Kumar Karna	Efficacy of Intermittent Fasting on Hepatic Enzymes, Fat Content, and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2453	Dr Sameera Sameera	Impact of Prior Drug Allergies on severity of drug-induced liver Injury , a study from tertiary care hospital Pakistan
2455	Javaria Younas Muhammad Younas	Diabetes association with liver diseases and prognostic risk factors of liver-related complications in diabetic patients.
2456	Mohamed Elsaid	Rurality and Neighborhood Socioeconomic Deprivation as Predictors of Hepatocellular Carcinoma Surveillance Adherence Among Adults with Cirrhosis in the United States
2458	Said A. Al-Busafi	Wilson's Disease in Oman: A National Cohort Study of Clinical Spectrum, Diagnostic Delay, and Long-Term Outcomes
2459	Mohamed Elsaid	Superinfection with Hepatitis Delta Virus Elevates the Risk of Hepatocellular Carcinoma in Individuals with Chronic Hepatitis B Virus Infection
2462	Said A. Al-Busafi	Prevalence, risk factors, and demographic insights of sickle cell hepatopathy in Omani adolescents and adults: A retrospective analysis
2464	Said A, Al-Busafi	Beyond Liver Function: Albuminuria and a novel Child-Turcotte-Pugh-AlbU score improve mortality prediction in medical intensive care unit patients with hepatic encephalopathy
2466	Dilip Makhija	Real-World Impact of Cardiovascular Comedications on DDI risk in Patients receiving direct-acting antiviral (DAA) Hepatitis C Therapy
2467	Kamuran Türker	A case of acute hepatitis C that resolved spontaneously
2468	Dilip Makhija	Antipsychotic Comedication and Drug-Drug Interaction Risk in US Patients Treated with HCV DAAs: Focus on PWUD, Healthcare Resource Use Impact, and AASLD Algorithm Implications
2469	Amarsanaa Jazag	Study on Patients Undergoing Triple Therapy for Liver Steatosis in Mongolia
2470	Amarsanaa Jazag	Causes of New Hepatitis Virus Infections in Mongolia
2471	Azjarga Maidar	Comparative Study of Liver Indicators in Patients with and without Diabetes Mellitus
2472	Agnist Bazarbadnaa	Correlation Between the Degree of Liver Steatosis and Liver Enzyme (ALT, AST, GGT) Levels
2473	Uranzaya Enkhtuvshin	Correlation Between Blood Triglyceride and Cholesterol Levels in Individuals with Liver Steatosis
2474	Davaajan Munkhdelger	Determining Risk by Glucose and Triglyceride Ratio in Individuals with Liver Steatosis
2475	Soyol-Erdene Agchvayabazar	Correlation Between Liver Fat Accumulation Level and Body Mass Index
2476	Bujin-Ujin Badam	The Impact of Changes in Liver Enzymes and Body Mass Index on Liver Fibrosis
2478	Saddiqa saeed Saeed Ahmed	Association of MAFLD with joint lifestyle exposures Background & aims
2479	NEANG NOV	Epidemiological, Clinical, and Paraclinical Profile of Decompensated Liver Cirrhosis at Khmer-Soviet Friendship Hospital, a Tertiary Hospital in Cambodia
2482	Han Ah Lee	Comparative Efficacy and Safety of Second-Line and Later Systemic Therapies After First-Line Treatment Failure in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
2485	Tuğba Gürsoy Koca	Hepatic Dysfunction in Critically Ill Children: Prognostic Value of PRISM III and PELOD-2 Scores in the Pediatric Intensive Care Unit
2486	Jae Youn Cheong	Targeting a Cytosolic Nucleotide Pyrophosphatase Suppresses Malignant Phenotypes of Hepatocellular Carcinoma
2487	CHHIT Dimanche	Clinical and Laboratory Profile of Ascites in Decompensated Liver Cirrhosis and Prevalence of Spontaneous Bacterial Peritonitis: A Retrospective Study at Khmer-Soviet Friendship Hospital
2489	Ozgur Aktas	HEPATOCELLULAR CANCER RISK IN CHRONIC HEPATITIS D AND CHRONIC HEPATITIS B PATIENTS WITH EFFICIENT TREATMENT: A PROPENSITY WEIGHTED ANALYSIS
2490	Hasmik Ghazinyan	A Rare Case of Zieve's Syndrome in a cirrhotic patient: Hemolytic Anemia Associated with Alcoholic Liver Disease and Hyperlipidemia
2492	Arjun Maria	Development and validation of an artificial intelligence driven convolutional neural network for automated stool colour classification to facilitate early diagnosis of biliary atresia
2493	Arjun Maria	Impact of continuous renal replacement therapy on survival and ammonia clearance in pediatric acute liver failure with advanced hepatic encephalopathy: a two-centre retrospective cohort analysis
2494	Arjun Maria	Clinically significant weight loss through combination of glp-1 agonist and sedation-free swallowable intragastric balloon in prader–willi syndrome with severe cardiopulmonary risk
2495	Arjun Maria	Non-destructive Epstein Bar Virus-associated post transplant lymphoproliferative disorder presenting with gastrointestinal bleeding in a post-liver transplant child: diagnostic and therapeutic challenges
2497	Jiahao Han	Hepatic Hemodynamics Detected by Ultrasound Localization Microscopy is Improved after Transjugular Intrahepatic Portosystemic Shunt
2498	Heejoon Jang	Liver disease severity and comorbidity in HBV mono-infection versus HBV/HDV co-infection: a population-based study

Paper No	Presenter	Title
2500	Sanal MG	Adipokine dysregulation in adipose tissue in cirrhosis
2501	Selma Tosun	Evaluation of the Effect of the National Hepatitis B Vaccination Programme on Hepatitis B Seroprevalence (Healthcare worker and community-based assessment)
2502	Devrim Muge Ozari Gulnar	Turkish Real-World Effectiveness and Safety of Bulevirtide in Chronic Hepatitis Delta: A Multicentric Experience with Long-Term Follow Up
2503	Ahmed Nagy	Tumor Lysis Syndrome Following Atezolizumab–Bevacizumab Therapy in Advanced Hepatocellular Carcinoma: A Rare and Life-Threatening Complication
2509	Hayk Harutyunyan	Feasibility And Limitations Of Living Donor Liver Transplantation In Armenia
2512	Selma Tosun	Evaluation of the 24-year prognosis of patients with inactive HBsAg carriage
2516	SELMA TOSUN	Evaluation of the 24-year prognosis of patients with inactive HBsAg carriage
2517	shasha li	Is primary biliary cholangitis excluded in patients negative for PBC-specific autoantibodies and without cholestatic features?
2520	Mehmet Hadin Karadağ	A RARE CASE IN LIVING DONOR LIVER TRANSPLANTATION: GRAFT-TO-GRAFT OF PORTAL VEIN ANASTOMOSIS
2521	Pattida Kongsomboonchoke	A novel clustered regularly interspaced short palindromic repeats-based assay for intrahepatic hepatitis B virus covalently closed circular DNA quantification
2522	Cleo Christille Lynn Lom-oc	Triple Trouble: A Case of Hepatocellular Carcinoma in a Patient with Previous Renal and Colonic Malignancies
2523	Ketsarapohn Sudchit	HepPlus: Protocol for a multicenter study of a web-based platform to support hepatitis B and C management in Thailand
2524	Zhujun Cao	Baseline Albumin Structural Defects and Soluble Inflammatory Markers Identify Poor Responders to Albumin Therapy in Cirrhosis
2526	Jiwoong Jang	Differences between non-alcoholic liver disease and alcoholic liver disease-related HCC
2528	Tatia Khachidze	Gut Microbiota Dysbiosis and Its Role in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease
2529	Vahe Azatyan	Clinical Manifestationsof of the Oral Mucous in Patients with Viral Hepatitis C in Armenia 2025 Years
2530	Sung Woo Cho	Fibroblast- and macrophage-derived thrombospondin-1 orchestrates the fibroinflammatory niche in metabolic dysfunction-associated steatohepatitis-induced fibrosis
2532	Ram Prasad Sinnanaidu	COMPARISON OF ATTENUATION PARAMETER AND LIVER STIFFNESS MEASUREMENT BETWEEN HEPATUS AND FIBROSCAN IN PATIENTS WITH CHRONIC LIVER DISEASE: A PROSPECTIVE STUDY
2535	LingYu Kong	Regulation and Clinical Translation of m⁶A Modification in Intrahepatic Cholangiocarcinoma
2536	Dr. Aftab Abbasi	ANTIFIBROTIC EFFECTS OF ANGIOTENSIN RECEPTOR BLOCKERS IN ORGANOPHOSPHATE (CHLORPYRIFOS) INDUCED LIVER FIBROSIS
2537	Lingga Gumelar	Correlation of interleukin-17 serum levels with degree of liver fibrosis in chronic hepatitis B patients at Mohammad Hoesin Hospital Palembang
2538	Lingga Gumelar	Comparison of sensitivity and specificity of vascular endothelial growth factor and alpha-fetoprotein levels in detecting hepatocellular carcinoma in patients with hepatitis b-related liver cirrhosis at Mohammad Hoesin Hospital Palembang
2539	Adhitya Wicaksana	Association Between Clinical Predictors And Albumin Billirubin Score In Hepatocellular Carcinoma Patients Receiving Lenvatinib At Dr. Mohammad Hoesin General Hospital, Palembang, During 2025
2540	Kübra YILDIRIM	Fulminant Hepatic Failure Following Antiviral Therapy Discontinuation in Chronic Hepatitis B: A Fatal Case
2542	Xiaoyong Ye	Construction of an imaging-omics machine learning prediction model for post-liver transplantation recurrence of liver cancer based on ECV
2544	Sam Fandood	Comparison of Predictive Accuracy of Monocyte-to-Lymphocyte Ratio (MLR), Neutrophil-To-Lymphocyte Ratio (NLR), and Systemic Immune-Inflammation Index (SII) for Colonoscopic and Clinical Outcomes among Patients with Gastrointestinal Tuberculosis (GITB)
2545	Sam Fandood	COMPARISON OF CLINICAL OUTCOME AND ENDOSCOPIC FINDINGS BETWEEN ACIDIC AND ALKALI CAUSTIC INJURIES IN A TERTIARY REFERRAL HOSPITAL
2546	Sam Fandood	Use of Double Plasma Molecular Adsorption System (DPMAS) in Intrahepatic Cholestasis of Pregnancy Refractory to Medical Management: A Case Report
2547	Sam Fandood	When the Liver Speaks for the Vessels: A Diagnostic Odyssey of a rare case of Non-HBV-Associated Polyarteritis Nodosa Presenting with Jaundice and Transaminitis
2548	Sam Fandood	Multiverse of Upper Gastrointestinal Tuberculosis: A case series of GITB with involvement of Esophagus, Gastric and Duodenal TB
2549	Sabir Ali	Outcome Of Patients Presenting With Upper Gastrointestinal Bleeding: A Single High Volume Center Prospective Study
2550	Anjab Akmal Sya'roni	PROGNOSTIC VALUE OF THE ALBUMIN-BILIRUBIN SCORE FOR VARICEAL REBLEEDING AND HEPATIC ENCEPHALOPATHY-RELATED HOSPITALIZATION IN CIRRHOTIC PATIENTS WITH CHRONIC HBV INFECTION
2551	Feng Gao	Noninvasive Detection of Metabolic dysfunction-associated steatohepatitis and Fibrotic Burden Using Ultrasound-Derived LIID and liver stiffness measurement in Metabolic dysfunction-associated steatotic liver disease: A Multicenter Study.
2552	ALYSSA CHAN	DPMAS-Induced Stabilization in a Terminal Patient: Short-Term Benefit in the Face of Terminal Prognosis
2555	Jayadevan K	: A Preclinical study on Protective Effects of Atorvastatin Against Methotrexate-Induced Hepato-Renal Toxicity: Role of Oxidative Stress and Inflammation
2556	Junying Li	Clinical Benefit of Perioperative Prophylactic Antibiotics in Hepatocellular Carcinoma (HCC) Patients Undergoing Transcatheter Arterial Chemoembolization (TACE)
2557	Jie Li	Silybin Attenuates Liver Fibrosis by Suppressing Hepatic Stellate Cell Activation

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2558	Yali Ji	Diagnostic Performance of Baveno VII Criteria in a Real-World, Multicenter Cohort Across Liver Disease Etiologies
2561	Adhitya Wicaksana	Correlation Between Platelet Derived Growth Factor-BB As Liver Fibrosis Biomarker and Degree Of Liver Fibrosis Based On Fibroscan On Chronic Hepatitis B
2563	Jong Jin Hyun	Is Laparoscopic Cholecystectomy Necessary at an Asymptomatic Stage?
2566	Van Trung Huynh	Serum DCP and GALAD Score Reflect Tumor Burden and Stage Progression More Accurately Than AFP-Based Markers in Intermediate and Advanced Hepatocellular Carcinoma
2567	Van Trung Huynh	Prediabetes as an Early Clinical Indicator of Advanced Liver Fibrosis in Non-Diabetic MASLD Patients: A Non-Invasive Risk Stratification Study
2568	gaomin gao	Gut-Liver Axis-Mediated Dysbiosis in the Pathogenesis of Liver Fibrosis and Intervention Strategies
2569	Jing Wang	Clinical Characteristics and Complication Patterns in Hospitalized Elderly Patients with Liver Cirrhosis: A Single-Center Retrospective Analysis of 1,736 Admissions
2570	ilkay bozkurt	Improving HBV Screening and Prophylaxis in Rituximab-Treated Patients: A Quality-Improvement Study
2571	Dianliang Fang	Predicting key components and mechanisms of silymarin in treating sepsis-related liver injury using GraphBAN
2573	Peng Qu	NRF2-Mediated Gsta3 Transcriptional Activation Protects Against Sepsis-Associated Liver Injury
2575	Ahmet Biçici	Acute Pancreatitis Secondary to Tirzepatide Therapy
2578	Xinhao Gao	Integrated Multi-omics Liquid Biopsy: Advancing Early Detection and Precision Management of HCC
2581	Keiichi Katayama	Association between Acid Suppressant Use and Hepatic Encephalopathy in Patients with Liver Cirrhosis: An Inverse Probability of Treatment Weighting Analysis
2582	Wenhao Xue	Neurological Outcomes and Survival in Hepatic Myelopathy A Multicenter Cohort Study
2584	shufang pan	Cytopenia Following Albendazole Use: A Real-World Observation
2585	Jie Gao	Clinical Characteristics of Non-Cirrhotic Portal Hypertension Associated with Oxaliplatin
2586	Shiheng LIU	The traditional Chinese medicine prescription Danjin Shugan Formula exerts anti-fibrotic effects by regulating the mTOR-S6K1/4E-BP1 signaling pathway and YAP/TAZ proteins
2587	Trung Huynh Van	Genetically Confirmed Dubin-Johnson Syndrome Presenting as Long-Standing Isolated Conjugated Hyperbilirubinemia
2588	Pınar Korkmaz	Epidemiology of Delta Virus Infection in Turkey: Current Seroprevalence
2589	Trung Huynh Van	Adult-Onset Wilson Disease Without Classical Features: Diagnostic Value of ATP7B Genotyping and Leipzig Scoring
2591	Trung Huynh Van	AMA-negative Primary Biliary Cholangitis Diagnosed by a Reproducible Dechallenge-Rechallenge Response to Ursodeoxycholic Acid
2592	Jie Liu	Ultra-High HBV Viral Load Not Equivalent to the Immune-Tolerant Phase.
2595	Hua Liu	A case of artificial liver support system for Wilson’s disease related acute-on-chronic liver failure complicated with hyperthyroidism
2597	Jingjing Wang	Asthenia-Anaemia-Liver cirrhosis-Brucellosis
2598	Hua Liu	Research on Artificial Liver Treatment for Non-Hepatocellular Carcinoma Patients with Severe Immune Checkpoints Related Liver Injury
2599	Loreta A. Kondili	Residual metabolic and steatotic risk in chronic viral hepatitis: real world evidence from the Italian PITER cohort
2603	GİZEM DAĞCI	Prevalence and Diagnostic Variability in Cirrhotic Cardiomyopathy: A Meta-analysis
2610	Yan Xu	Comparative Efficacy of Combined Targeted and Immunotherapy Regimens in Unresectable Hepatocellular Carcinoma: Impact on Survival and Conversion Surgery Outcomes
2611	Jie Xue	Pre-emptive Transjugular Intrahepatic Portosystemic Shunt Improves Survival in Advanced Cirrhosis Patients with Gastric Fundal Variceal Bleeding: A Multicenter Cohort Study
2613	jiao qin	Development and validation of a time-stratified risk model for acute variceal bleeding in hepatocellular carcinoma
2615	Malika Khassenova	Liver graft rejection after liver transplantation in Kazakhstan: a single center experience
2616	Ramilya Abdieva	The influence of hepatitis HBV, HCV and HDV viruses on the development of sarcopenia in patients with liver cirrhosis
2618	Feihu Bai Bai Feihu	Alistipes putredinis Alleviates Metabolic-Associated Fatty Liver Disease via the Acetate-GPR43 Axis by Suppressing Neutrophil ROS Generation
2619	Daya Zhang Zhang Daya	Enterotoxigenic Bacteroides fragilis Exacerbates Alcoholic Liver Disease by Driving Host Metabolic Reprogramming via the Tryptophan-Kynurenine-Retinol Pathway
2621	妍 娄	Construction and Evaluation of a Nobiletin Hepatic-Targeted Nanodelivery System for the Treatment of MASLD
2622	Shaoya Li	Itaconic acid improves MASH through regulating ferroptosis by Nrf2/HO-1
2624	pengyu pan	Risk Factors for Liver Fibrosis Severity in Patients with Nonalcoholic Steatohepatitis: A Study Based on Liver Pathology
2628	Eman Fares	Effect of Rifaximin on Platelet Count in Hepatitis C–Related Liver Cirrhosis: A Randomized Controlled Clinical Trial
2629	Songting Wu	Clinical characteristics and risk factors for early liver function abnormalities in young adults with MAFLD

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2631	Jinhui Wei	High ammonia promotes EHHADH-dependent pyrimidine degradation to induce inflammatory cell death in HCC
2632	da wang	Study on the Efficacy and Mechanism of the Spleen-Strengthening and Lipid-Regulating herbal formula in Treating MAFLD: An Exploration Based on the PPAR Pathway
2633	Christine Velasquez	Chylous Ascites in Liver Cirrhosis: Diverse Mechanisms, Diagnostic Challenges, and Multidisciplinary Management — A Case Series
2636	Xi Zhao	Macrophage ACAT1 aggravates alcoholic hepatitis by inducing mitochondrial damage and NLRP3 activation
2637	Ping-Lun Hsieh	Predictors of minimal clinically important improvement in cardiorespiratory fitness following unsupervised exercise training in metabolic dysfunction-associated steatotic liver disease
2638	Jiajie Li	Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: advantaged populations and HBeAg-negative patients
2642	Abegail Jayne Amoranto	Design, development, and pilot evaluation of a comprehensive liver disease registry in the Philippines
2645	Yaoyao Mao Mao	Traditional Medicine Yiqi Huoxue Relieves Nonalcoholic Steatohepatitis by Remodeling Intestinal Microbiota and Metabolites
2646	Xing Liu	Exploring the Predictive Value of the DiabetesLiver Score for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and MAFLD Based on the Dual Disease Nursing Management Model
2648	Jing Chen	Comparative Analysis of WHO 2024, EASL 2025, AASLD/IDSA 2025, and APASL 2026 CHB Treatment Guidelines: Implications for Treatment Eligibility and Antiviral Management Strategies
2650	Hongxia Chen	The Evolving Role of Vitamin D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Pathogenesis to Clinical Practice – An Updated Synthesis for 2026
2651	Jiyuan Zhou	A Systems Cross-omics Framework Uncovers Microbiota-Driven Molecular Targets for MAFLD Therapy
2652	Wenli Jiang	A retrospective study on nirmatrelvir/ritonavir and azvudine in treating COVID-19 in patients with cirrhosis
2653	Peng Hu	From Prediction to Decision: A Dynamic Multi-Modal Causal Machine Learning System for Optimized Clinical Management of Chronic Hepatitis B in a 150,000-Patient Longitudinal Cohort
2655	shiji wu	Single-Cell Trajectory and Communication Profiling Reveals a Metabolic-Death Switch Driven by Macrophage Polarization in Hepatocellular Carcinoma Radioresistance
2656	Liza Thomas	Relationship of liver fibrosis risk score (FIB-4) with echocardiographic findings in myocardial infarction with non-obstructive coronary artery disease (MINOCA)
2657	Li Wenting Li	Clinical characteristics and influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis with esophageal and gastric variceal rupture and bleeding in the Western Region of
2658	Jingjing Wang	Real-world impact of 48-week tenofovir amibufenamide therapy on lipid profiles in chronic hepatitis B
2659	Shi-Heng Liu	Agenesis of the Dorsal Pancreas Caused by HNF-1β Gene Mutation Presenting with Abnormal Liver Function as the Initial Manifestation: A Case Report
2661	Yufeng Xing	Macrophage metabolic reprogramming mediated by PKM2 deacetylation in liver fibrosis
2662	Jing Chen	Exploring the Dose-Response of Shugan Xiaozhi Formula Granules and MRI Radiomics-Based MAFLD Prediction
2665	Eman Fares	Evaluation of the Egyptian Club of Ascites Diagnostic Algorithm for Etiological Diagnosis of Ascites: A Single-Center Study”
2667	Xi He	HBV recurrence in patients with hepatocellular carcinoma and cholangiocarcinoma following liver transplantation
2668	Daniele Alek Calda	Efficacy and Safety of Elobixibat in Patients with Chronic Constipation: A Meta-Analysis of Randomized Controlled Trials
2669	Zhigang Ren	Multicohort metagenomic analysis of cholangiocarcinoma: non-invasive diagnosis and functional validation of key microbes
2674	lei luo	Model combining MELD-ICG R15 and systemic immune-inflammation index predicts 28-day clinical progression in hepatitis B virus-related acute-on-chronic liver failure patients
2675	Yufeng Xing	The Mechanism of Necroptosis in Metabolic dysfunction-associated Fatty Liver Disease and related targeted therapy
2676	Bo Yang	the Mechanism of Ruangan Formula in Regulating Macrophage Glycolysis for the Prevention and Treatment of Liver Fibrosis via SIRT1-Mediated PKM2 Deacetylation
2677	Jing Chen	Barriers and Facilitators to Chronic Hepatitis B Management in Primary Care: A Systematic Review from Patient and Physician Perspectives
2680	Md. Shakhawat Hossain	Evaluation of NLR as a novel Predicting biomarker for Disease Severity and Clinical Outcomes in Acute Hepatitis A and E
2682	Lili Zhao	Isolated Pancreatic tuberculosis masquerading as Malignancy in a patient with drug-induced liver injury: A case report
2683	Yang Li	Prior Tyrosine Kinase Inhibitor Therapy Is Associated with an Increased Risk of Hepatitis B Virus Reactivation in HBV-Related Hepatocellular Carcinoma Patients with Undetectable HBV DNA Receiving PD-1 Inhibitor–Based Combination Therapy
2684	Yuxin Liang	Hydrogen sulfide donor S-Propargyl-cysteine remodels the HCC microenvironment and enhances immunotherapy efficacy: an integrated metabolomic and molecular analysis
2685	Pin Han	Early diagnostic and analysis of the hihg risk factors of covert hepatic encephalopathy

Paper No	Presenter	Title
2686	ZiWei Yuan	Multisystem Crosstalk in MAFLD: An Integrative Perspective from Organ Dialogue to Hepatic Pathology
2687	Guangqi Zhu	The Mediating Roles of HOMA-β and TG/HDL-C in the Associations of General and Central Adiposity with metabolic dysfunction-associated fatty liver disease: A Cross-Sectional Study
2688	lei luo	Immediate Improvement in HCV RNA Testing Following Active In-Hospital Management: An Interrupted Time Series Analysis
2692	Sayan Malakar	Predictors of recompensation in autoimmune hepatitis related decompensated cirrhosis following immunosuppressive therapy in India
2694	Eman Fares	Comparison of Diagnostic Performance of Non-Invasive Steatosis and Fibrosis Scores and Ultrasound versus FibroScan in Metabolic-Associated Fatty Liver Disease
2696	Eman Fares	Map of Digestive and Liver Diseases in Egypt
2697	ALONZO, UZZIEL ROMAR S. ALONZO	Demographic Profile and Clinical Indications of Patients Undergoing Liver Elastography in a Tertiary Government Hospital: A Pilot Study
2698	lei luo	Model combining MELD-ICG R15 and systemic immune-inflammation index predicts 28-day clinical progression in hepatitis B virus-related acute-on-chronic liver failure patients
2701	Wanwan Shi	MSC-mediated Modulation of the IL-4/CD39 Axis in Treg cells Restores Immune Tolerance and Improves Treatment Outcomes in Steroid-Resistant Autoimmune Hepatitis
2702	Sanjeevani Kaul	Modified Leipzig (Leipzig-U) score is equally helpful for the early diagnosis of Wilson disease in children presenting with liver disease
2703	Petr Piza	Sequential plasma adsorption and therapeutic plasma exchange for extreme hyperbilirubinemia in Budd–Chiari syndrome with acute-on-chronic liver failure
2704	Jiwoong Jang	Differences between non-alcoholic liver disease and alcoholic liver disease-related HCC
2705	Yan Yan	Early Expansion of CCR7⁻PD-1⁺ NK Cells and HBsAg Decline Predict Interferon-Induced Immune Reconversion in Chronic Hepatitis B
2707	Liteng Lin	Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC
2708	Jiaojiao Zhu	Risk Factors and Development of a Predictive Model for Chronic Kidney Disease in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease
2709	Wenjun Du	Machine Learning-Based Prediction of Incomplete UDCA Response in Primary Biliary Cholangitis: Model Development and Assessment
2710	Ping Li	Construction of nomogram based on inflammatory markers to predict recurrence and survival of single small hepatocellular carcinoma after radiofrequency ablation
2712	Siqian Lu	Development and Validation of a Nomogram Incorporating Thyrotropin and Metabolic Parameters for Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease Risk: A Cross sectional study
2713	Yelei Cen	TRAF2 Deficiency Aggravates Mitochondrial Dysfunction Through PI3K-AKT Pathway Inhibition in Acetaminophen-Induced Liver Injury
2715	Qi Yang	Va-Cur@Lips Inhibits the Metastasis of Hepatocellular Carcinoma by Targeting the Peri-Tumoral Fibrotic Microenvironment
2716	Qi Yang	Preoperative prediction power of radiomics and non-radiomics fusion model based on US-CEUS for microvascular invasion of hepatocellular carcinoma:A multicenter study
2717	Saut Horas H Nababan	Clinical Profile Comparison Between HBeAg-Positive and HBeAg-Negative Hepatocellular Carcinoma Patients: Highlighting Advanced BCLC Staging and Low Antiviral Treatment Uptake in an Indonesian Cohort Analysis
2718	Hao Shen	Interpretable Deep Learning model to Predict Multi-Outcome Trajectories of MASLD Using Whole Slide Images and Time-Series Data: A Retrospective, Multicentre Study
2719	Haoran Hu	Periportal Arginine Deficiency Drives Macrophage Senescence to Blunt Aged Liver Regeneration
2720	Siwanon Nawalerspanya	PRE-EXISTING ANEMIA INVERSELY RELATED TO RIBAVIRIN INDUCED ANEMIA IN CIRRHOTIC PATIENTS WITH VIRAL HEPATITIS C INFECTION
2721	Lu Bai	Prevalence, Characteristics, and Prognostic Value of Pituitary-Target Gland Axis Dysfunction in Decompensated Cirrhosis: A Prospective Cohort Study
2722	Ping Li Li	The predictive value of serum ferritin for Biochemical Non-resolution (BNR) in DILI
2723	Lei Luo	The Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Liver Stiffness in Chronic Hepatitis B Patients: A Cohort Study
2724	Xiaohui Zhang	Silybin Capsules Protected Hepatocytes by Regulating Mitochondrial Homeostasis in the Organoid Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
2725	Chi Wang	Suppression of gene expression of cholesterol in liver by royal jelly
2726	Lu Peng	Endothelial peroxisome proliferator-activated receptor α prevents acetaminophen hepatotoxicity via maintenance of endothelial junctional integrity
2727	Peng Chen	HBV enforces interferon refractoriness by hijacking LUBAC-mediated IRF9 linear ubiquitination
2728	Peng Chen	Secretory ECM1a restores HBV-specific CD8⁺ T Cell response via integrin β1 blockade to promote HBsAg loss in chronic HBV infection
2730	Yıldız Buse Koreli	Association of monocyte-to-high-density lipoprotein cholesterol ratio with liver histopathology in chronic hepatitis b
2732	Alexander Nersesov	Comparative evaluation of paper and digitized cognitive tests for diagnosis of hepatic encephalopathy in patients with liver cirrhosis
2734	wei xiang	A Multidimensional Prognostic Signature Integrating a 4-Gene Panel, Immune Contexture, and Radiomic Features Predicts Progression-Free Survival in Hepatocellular Carcinoma

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2735	Jun Lu	Significance of fibrinogen,D-dimer,albumin and NLR in the progression of Acute-on-Chronic pre-liver failure
2737	Qing-Lei Zeng	Effect of peginterferon alfa-2b with or without nucleos(t)ide analogues on long-term outcomes in chronic hepatitis B: Preliminary 48-week results from the multicenter, prospective VISION study in China
2738	Jun-Hao Mei	Causal Machine Learning–Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma
2740	yueying chen	Hepatocyte TrkB acts as a gatekeeper against MASH-related liver fibrosis by suppressing the TGFβ/CCL2 axis and macrophage infiltration
2741	Diğdem KURU ÖZ	Magnetic Resonance Cholangiopancreatography-Based Radiologic Evaluation of Biliary Complications in Living Liver Donors: A Single-Center Imaging Study
2743	Ninda Septia Yuspar	Immune Signatures Across Chronic Hepatitis B Phases: Serum IFN-γ and CD8+ T-Cell Counts in Untreated Patients at Dr. Mohammad Hoesin Hospital, Palembang, Indonesia
2744	Qin-qin Liu	Paracaval Triangle: A Novel Anatomic Landmark for Central Hepatectomy
2745	Qin-qin Liu	Laparoscopic Anatomical liver resection using ICG-positive staining combined infrared laser-guided
2746	Marrium Sultan Dar Dar	Sofosbuvir/Velpatasvir/Voxilaprevir in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
2747	Chelsea Colleen Paris	Hepatic Artery Pseudoaneurysm Presenting Overt Obscure Gastrointestinal Bleeding
2749	Nida Rasool	Beyond the Stomach: Rapunzel Syndrome Presenting with Sepsis and Multi-organ Failure
2750	Nida Rasool	Role of “PAST-F model” in predicting advanced liver fibrosis in Autoimmune Hepatitis
2751	Jingyi Si	Fucoidan Alleviates MASH by Inhibiting JNK Phosphorylation-Mediated Hepatocyte Apoptosis
2752	Zhuomiaoyu Chen	Protein phosphatase regulatory subunit enhances scaffold protein expression through an RNA binding protein and promotes invasion and immune remodeling in intrahepatic cholangiocarcinoma
2754	Diğdem Kuru Öz	THE CONTRIBUTION OF MRCP IN DETERMINING THE NEED FOR ENDOSCOPIC INTERVENTION IN ANASTOMOTIC BILE DUCT STRICTURES IN LIVER TRANSPLANT RECIPIENTS
2755	Chihao Zhang	The Ptn-Sdc2 axis regulates meningeal fibrosis and lymphatic function in hepatic encephalopathy
2757	Tanveer Hussain	Diagnostic Accuracy of Leukocyte Esterase Dipstick Test in Early Detection of Spontaneous Bacterial Peritonitis in Cirrhotic Patients
2758	Afzalun Nessa Nessa	Mutation Profiles of three selected driver genes from Circulating cfDNA as Non-Invasive Prognostic Biomarkers in HBV-Induced Hepatocellular Carcinoma
2761	Danielle Lucero	CORRELATION OF NON-INVASIVE FIBROSIS TEST RESULTS WITH THE NUMBER OF METABOLIC RISK FACTORS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
2763	Rohit Shetty	Comparison of Body Composition Parameters Between Cirrhotic and Non-Cirrhotic MASLD patients
2766	Hyunjae Shin	Association of radiotherapy with atezolizumab plus bevacizumab with survival in advanced hepatocellular carcinoma
2767	Xue Jiao	Diagnostic value of homocysteine combined with IgG in differentiating drug-induced liver injury and autoimmune hepatitis
2768	GUO Feng	Diagnostic Value of the SS-FIB-VT Model Integrating Spleen Stiffness, Fibrinogen, and Retinal Vessel Tortuosity for High-risk Esophageal Varices in Liver Cirrhosis
2769	Mery Friyanti Pandiangan	"Diabetic Ketoacidosis After Laparoscopic Cystectomy for Hydrosalpinx: A Case Illustrating Postoperative Metabolic Vulnerability"
2770	Esra Taşgetiren	The Value of Serum Immature Granulocyte Levels in Predicting Disease Activation in Patients with Ulcerative Colitis
2771	Arif Mansur Cosar	Infliximab as Salvage Therapy in Multidrug-Resistant Autoimmune Hepatitis: A Seven-Year Clinical Course
2772	Antony Kahwagi	Development of a new nutritional screening score in hospitalized patients with cirrhosis.
2775	Liming Zheng	Circadian Rhythm Disruption Induces Abnormal Serine Metabolism and Immune Suppression to Promote Hepatocellular Carcinoma Progression
2776	Ammar ALRAMADAN	Serum Vitamin A, D and B12 Levels and Their Association with Disease Severity and Treatment Response in Chronic Hepatitis C
2777	Andry Kurniawan	Profile of HSD17B13 rs72613567 TA allele Variant in Indonesian Patients With Metabolic Dysfunction–Associated Fatty Liver Disease and Type 2 Diabetes Mellitus and Its Association With Liver Steatosis Severity
2778	Ammar ALRAMADAN	A Novel Non-Invasive Index for Predicting Non-Alcoholic Fatty Liver Disease in Patients with Chronic Hepatitis B: The Hatay Index
2780	Gulziba Kurax	Antiviral therapy in treatment-naive patients with hepatitis B-related cirrhosis and low-level or undetectable viremia: long-term outcomes
2782	Junkai Ma	Liver Cirrhosis Promotes Hepatocellular Carcinoma Progression by Regulating Myeloid Differentiation in Spleen
2783	Janaka Subasinghe	Methyldopa -induced acute liver failure successfully managed with drug withdrawal and supportive care - A case report
2786	pitt akbar	Restoring sleep in cirrhosis: A prospective three arm double blind randomized clinical trial of lemborexant efficacy and hepatic safety
2787	Vamsi krishna Ankam	Variceal bleeding due to stride - immunotherapy induced or cirrhosis driven ?
2788	Paul Ian Banchiran	Double plasma molecular adsorption system (DPMAS) for liver failure: early institutional experience at a tertiary hospital in the Philippines
2790	Ammar ALRAMADAN	Prevalence and clinical correlates of metabolic burden and fibrosis severity among non-cirrhotic HBsAg-positive patients

APASL 2026 Istanbul

35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org

Paper No	Presenter	Title
2791	YiFan Gao	Research on Resveratrol-loaded Tetrahedral Framework Nucleic Acids and Their Therapeutic Mechanisms for Metabolic Dysfunction-Associated Fatty Liver Disease
2792	Sabahat Çeken	Risk of Hepatitis B Reactivation Among HBsAg-Negative, Anti-HBc–Positive Breast Cancer Patients Undergoing Chemotherapy
2794	Leo Francis Gerardo	Extending Resectability in Fibrolamellar Hepatocellular Carcinoma Through Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): A Case Report
2795	Wanting Yang	Achieving Recompensation in Hepatitis B Cirrhosis via Targeted Albumin Infusion: A Multicenter Randomized Controlled Trial Protocol
2797	Leo Francis Gerardo	Incidental Multifocal Hepatic Masses in an Asymptomatic Patient: A Neuroendocrine Tumor in Disguise
2798	Leo Francis Gerardo	Small Bowel Obstruction Secondary to Post-Operative Adhesions and Gastrointestinal Vasculitis in Systemic Lupus Erythematosus: A Rare and Challenging Case
2800	Mahesh kumar Choudhary	An observational study to evaluate the incidence, clinical profile, risk factors of biliary complications in adult post–liver transplant recipients.
2801	Leo Francis Gerardo	A Rare Cause of Massive Painless Hematochezia: Acute Hemorrhagic Rectal Ulcer Syndrome in a Critically Ill Patient
2802	Jun Zheng	Melatonin Ameliorates LPS-Induced Acute Liver Injury via Upregulating Sirtuin 4(SIRT4) Expression and Inhibiting Macrophage Extracellular Trap(MET) Formation
2803	Ghadi Dagher	Medical Knowledge and Therapeutic Practices Regarding Hepatitis B and C: A Study Among Lebanese Physicians
2804	Zhouying Zheng	Sequential liver transplantation after combined therapy for hepatocellular carcinoma: rejection risk and management
2805	Mustafa Kemal Çelen	Evaluation of Factors Affecting Bone Mineral Density in Chronic Hepatitis B Patients Receiving Oral Antiviral Therapy "HEBDEM Study"
2806	Ghazi Abrar	Prevalence and Impact of Cirrhotic Cardiomyopathy on adverse outcomes following Liver Transplantation: A systematic review and a Meta-analysis
2807	Syedda Ayesha	Awareness of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in Healthcare Workers: A KAP Study
2808	Danish Kumar	HYPOALBUMINEMIA AS A PREDICTOR OF COMPLICATIONS IN PATIENTS WITH LIVER ABSCESS-A SYSTEMIC REVIEW AND META-ANALYSIS
2811	Samia Zainab	COMPARATIVE POTENTIAL OF DIFFERENT EDIBLE OILS TO IMPROVE THE STATUS OF NONALCOHOLIC STEATOHEPATITIS
2812	Ethan Steele	Plasma Signal Regulatory Protein-a, a potential biomarker to predict corticosteroid response and prognosis in patients with severe alcohol-associated hepatitis
2813	Hyunjae Shin	Differential therapeutic effectiveness of atezolizumab plus bevacizumab in unresectable HCC by CHB viral activity
2816	Zain Majid	Role of HbA1C in predicting Liver Fibrosis in MASLD patients: A Systematic Review and Meta-Analysis
2817	Nasir hasan Luck Luck	Efficacy of Sofosbuvir and Velpatasvir in Achieving Sustained Virological Response in Patients with End-Stage Renal Disease Infected with Hepatitis C Virus
2819	Nasir Hassan Luck Luck	Human leukocyte antigen DQ 2 and DQ 8 expression among renal transplanted patients with chronic diarrhea
2820	Raja Taha Yaseen Khan	Association of Low Vitamin D Levels with Non-Alcoholic Fatty Liver Disease in Lean Individuals: A Systematic Review and Meta-Analysis
2821	Yaditta Mirdania	TM6SF2 rs58542926 Gene Polymorphism and Liver Fibrosis in the Type 2 Diabetes Mellitus Population in Indonesia
2822	GERALDINE AREVALO	Tumor mutational burden and circulating tumor DNA mutation analysis using liquid biopsy samples from Filipino patients with hepatocellular carcinoma
2823	Jitendra Kumar singh	Continuous Terlipressin Infusion Plus Norepinephrine Versus Norepinephrine Alone in Acute Kidney Injury Associated With Acute-on-Chronic Liver Failure and Septic Shock: A Randomized Controlled Trial
2824	YiFan Gao	Resveratrol-Loaded Tetrahedral Framework Nucleic Acids Ameliorate MAFLD via the NF-κB Signaling Pathway
2825	owais wani	APRI Tracks FIB-4, Not Imaging-Based Liver Metrics, in Diabetic MASH: A Cross-Sectional Analysis
2826	owais wani	Association Between Duration of Type 2 Diabetes Mellitus and Hepatic Steatosis and Fibrosis Assessed by Transient Elastography.
2827	Dr vamsi krishna Ankam	Medical Management of Symptomatic Polycystic Liver Disease Using Intermittent Short-Acting Octreotide: A Cost-Effective Alternative
2828	Jia Chen	Pipecolic Acid Attenuates MASH by Suppressing Monocyte-derived Macrophage Recruitment via Activating GABA-A receptor to Inhibit CaMKII/STAT1 Signaling
2829	Xiangqian Wang	Trends and disparities in China’s metabolic-associated fatty liver disease burden from 1990 to 2021
2830	Bonnie Chun Kwan Wong	Temporal change of hepatitis C virus testing and treatment coverage in people who inject drugs in Hong Kong
2831	Janus P. Ong	Early implementation experience in developing a Research Electronic Data Capture (REDCap)-based liver disease biobank platform in a lower-middle income country
2835	Huilian Shi	Predictive value of oxygen resaturation rate and MAFLD for left ventricular hypertrophy in obstructive sleep apnea
2836	Xuhua Duan	Effectiveness and safety of transcatheter arterial chemoembolization with EqualSpheres beads in patients with unresectable hepatocellular carcinoma：a single-arm, multi-center, prospective study
2837	liyuan Xin	Effects of miR-124-3p Knockdown on Hepatocyte Apoptosis and Protein C Synthesis in Mice with Portal Vein Obstruction
2838	Imran Hasanoglu	ONWARD: Strengthening the clinical management of zoonotic hepevirus infections through coordinated European network with global linkages
2840	Eman Fares	Ultrasound-Based Assessment of Hepatic Steatosis in Rheumatoid Arthritis Patients: A Cross-Sectional Study
2842	Jiarui Zheng	Machine learning‑based mortality prediction models for non-alcoholic fatty liver disease in the general United States population
2843	Fan Li	IRE1α-mediated downregulation of CYP7A1 drives MASH-HCC progression and immune evasion via regulation of cholesterol metabolism

Paper No	Presenter	Title
2845	Bilgehan Aygen	Effectiveness and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Patients Diagnosed with Chronic Hepatitis C
2846	Sedat ÇİÇEK	Prevelance of Sarcopenia in Cirrhotic Patients and Its Association with Prognosis
2847	Jiarui Zheng	nfluential factors associated with the reduction of peripheral blood neutrophils by PegIFNα and predictive analyses
2849	Mega Dwi Septivani	A COMPUTATIONAL INTELLIGENCE APPROACH TO PREOPERATIVE LIVER FUNCTION ASSESSMENT
2850	Candra Carmelli Lavalle	Comparative efficacy of ursodeoxycholic acid and s-adenosyl methionine in reducing transaminases in patients with non-alcoholic steatohepatitis: a retrospective prospective cohort study
2852	Min Zheng	Homocysteine is a promising biomarker for predicting acute kidney injury in patients with cirrhosis
2853	ZiWei Yuan	Metabolic Dysfunction-Associated Fatty Liver Disease: Signalling and Organ Dialogue within the Systemic Metabolic Network
2854	Shouhan Yao	Nanotherapy based on Mesenchymal stem cell-derived extracelllar vesicles target ADAM17-mediated TREM2 shedding on macrophages to promote efferocytosis for acute liver failure treatment
2855	lingru li	Construction of an Intelligent Early Warning System for Chronic Liver Disease Comorbidities Based on Multimodal Data Fusion and Traditional Chinese Medicine Constitution
2856	Qun Zhang	Association of Pre-transplant Abstinence Duration <6 Months with Post-transplant Outcomes in Patients with Alcohol-Related Liver Disease
2857	yifan xia	Integration of Disease Susceptibility State Theory and Multimodal Artificial Intelligence: A Novel Paradigm for Early Warning of Chronic Liver Disease
2858	Hao Liu	Compound Kushen Injection inhibits the formation of malignant ascites by modulating metabolites in malignant hepatocellular carcinoma ascites and influencing immune cells.
2861	Arif Mansur Coşar	Diagnosis of acute hepatitis C
2862	YAO YUNLONG	Based Prediction of Metabolic Dysfunction-Associated Fatty Liver Disease: A Meta-Analysis of Algorithmic Performance
2863	YAO YUNLONG	Artificial Intelligence Driven Imaging Analytics in Liver Disease: A Systematic Review
2864	YAO YUNLONG	Natural Language Processing for Hepatology Knowledge Mining: A Review of Algorithmic Advances
2865	YAO YUNLONG	Machine Learning Models for Autoimmune Liver Disease Classification: A Meta-Analysis
2866	YAO YUNLONG	Computational Network Modeling in Immune-Mediated Liver Diseases: A Systematic Review
2867	zhengjian wang	Superior Survival with Direct Surgery Over TACE-Based Strategies in Hemodynamically Stable Patients with Spontaneously Ruptured HCC: A Multicenter Propensity Score-Matched Cohort Study
2868	Rui Wang	High prevalence of coronary atherosclerosis in HBV-related hepatocellular carcinoma and liver cirrhosis: a cross-sectional study
2869	Kübra YILDIRIM	Hepatitis B Reactivation During Leflunomide Therapy: The Importance of Pre-Immunosuppression Screening
2870	YAO YUNLONG	Risk Stratification of Liver Fibrosis Progression Using Machine Learning: A Meta-Analytical Evaluation
2872	YAO YUNLONG	Bibliometric and Topic Modeling Analysis of Global Research Trends in Liver Fibrogenesis
2873	Yichen Peng	Integrative Metabolomic and Cytokine Profiling Reveals a "Metabolic-Inflammatory" Signature in Chronic Hepatitis B Combined with Metabolic Dysfunction-Associated Fatty Liver Disease
2875	Yichen Peng	Integrative Metabolomic and Cytokine Profiling Reveals a "Metabolic-Inflammatory" Signature in Chronic Hepatitis B Combined with Metabolic Dysfunction-Associated Fatty Liver Disease
2880	Kiran Tabish Tabish	Albumin-Bilirubin (ALBI) score in predicting complications in patients with HCC undergoing curative Resection- a systemic review and Meta-analysis
2882	Syed Mudassir Laeeq	Hypoalbuminemia as a predictor of mortality in patients with acute cholangitis-a systemic review and meta-analysis
2883	Eman Fares	Real-World Effectiveness and Safety of Sorafenib in Advanced Hepatocellular Carcinoma: A Prospective Study from Fayoum, Egypt
2884	Sanjay Kirshan Kumar Kumar	Comparison of hepatic and extra hepatic scores in predicting mortality in patients with Hepatitis C related cirrhosis
2885	Sudhir Verma	Comparative prognostic utility of acute change in Liver stiffness measured using splenic versus liver probe in patients of Acute on chronic liver failure
2887	Nasir Hassan Luck Luck	Role of “MANLATA model” in predicting recurrence in patients with Hepatocellular carcinoma undergoing Trans Arterial Chemo-embolization
2889	Meryem Balci	Hepatitis B Reactivation and the Effectiveness of Antiviral Therapy in Patients Receiving Immunosuppressive Therapy: A Real-World Study
2890	Najah R Zayyani Zayyani	Correlation of Abdominal Girth with Liver Shear-Wave Elastography in Non-Diabetic Population with Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
2891	Syed Mudassir Laeeq Laeeq	Factors associated with clinical success of endoscopic management of Post-Cholecystectomy Bile Duct Injury: A Retrospective Analysis
2892	Kiran Tabish Tabish	Non-invasive predictors of Hepatorenal syndrome in decompensated chronic liver disease
2893	Syed Mudassir Laeeq Laeeq	Role of PAST-F model in predicting advanced liver fibrosis in Autoimmune Hepatitis

Paper No	Presenter	Title
2895	Bilgehan Aygen	Risk of hepatitis b virus reactivation in patients negative for hepatitis b surface antigen and positive for hepatitis b core antibody receiving biological agents
2896	Jyoti Bhutani	Usefulness and Yield of Whole Exome Sequencing in Paediatric Genetic and Metabolic liver disorders in a Tertiary Care Centre in North India
2898	Sang-Hoon Kim	Circulating miR-184 and miR-206 as Predictive Biomarkers for Early Recurrence in HBV-Related Hepatocellular Carcinoma: A Prospective Study
2899	Nida Rasool	Assocation of Metabolic-dysfunction Assocciated Steatotic Liver Disease with Dementia: An Updated Systematic Review and a Meta-analysis
2900	Yu Zhang	Spectrum effects and threshold drift of 24-hour urinary copper excretion in hypercupriuric referrals: implications for Wilson disease diagnosis
2901	Yu Zhang	Spectrum effects and threshold drift of 24-hour urinary copper excretion in hypercupriuric referrals: implications for Wilson disease diagnosis
2902	Devi Yulia Rahmi	Integrating Clinical Biomarkers with Machine Learning to Predict Hepatocellular Carcinoma in NAFLD
2903	Jinzhen Cai	Single-Center Experience in Complex Liver Transplantation